SIDLEY AUSTIN LLP 787 SEVENTH AVENUE NEW YORK, NY 10019 (212) 839 5300 (212) 839 5599 FAX |
BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG HOUSTON LONDON |
LOS ANGELES NEW YORK PALO ALTO SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C. | ||||
FOUNDED 1866 |
February 22, 2013
VIA EDGAR
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Re: | BlackRock Global Opportunities Portfolio, BlackRock International Opportunities Portfolio, BlackRock Health Sciences Opportunities Portfolio and BlackRock Science & Technology Opportunities Portfolio, each a series of BlackRock FundsSM |
(File Nos. 33-26305, 811-05742) |
Ladies and Gentlemen:
On behalf of BlackRock FundsSM, attached for filing are exhibits containing interactive data format risk/return summary information that mirrors the risk/return summary information in the Prospectuses of BlackRock Global Opportunities Portfolio, BlackRock International Opportunities Portfolio, BlackRock Health Sciences Opportunities Portfolio and BlackRock Science & Technology Opportunities Portfolio (the Funds), dated January 28, 2013, as filed pursuant to Rule 497(e) under the Securities Act of 1933, on February 4, 2013 (the 497 Filing). The purpose of this filing is to submit the 497 Filing in XBRL for the Funds.
Any questions or comments on the 497 Filing should be directed to the undersigned at (212) 839-5583.
Very truly yours,
/s/ Ellen W. Harris
Ellen W. Harris
Enclosures
cc: | Benjamin Archibald, Esq. |
BlackRock Advisors, LLC |
Sidley Austin (NY) LLP is a Delaware limited liability partnership doing business as Sidley Austin LLP and practicing in affiliation with other Sidley Austin partnerships.
Label | Element | Value | ||||
---|---|---|---|---|---|---|
Risk/Return: | rr_RiskReturnAbstract | |||||
Registrant Name | dei_EntityRegistrantName | BLACKROCK FUNDS | ||||
Prospectus Date | rr_ProspectusDate | Jan. 28, 2013 | ||||
Service Shares | BLACKROCK INTERNATIONAL OPPORTUNITIES PORTFOLIO
|
||||||
Risk/Return: | rr_RiskReturnAbstract | |||||
Risk/Return [Heading] | rr_RiskReturnHeading | Fund Overview Key Facts About BlackRock International Opportunities Portfolio |
||||
Objective [Heading] | rr_ObjectiveHeading | Investment Objective | ||||
Objective, Primary [Text Block] | rr_ObjectivePrimaryTextBlock | The investment objective of BlackRock International Opportunities Portfolio (“International Opportunities” or the “Fund”), a series of BlackRock FundsSM (the “Trust”), is to seek long-term capital appreciation. | ||||
Expense [Heading] | rr_ExpenseHeading | Fees and Expenses of the Fund | ||||
Expense Narrative [Text Block] | rr_ExpenseNarrativeTextBlock | This table describes the fees and expenses that you may pay if you buy and hold Services Shares of International Opportunities. | ||||
Operating Expenses Caption [Text] | rr_OperatingExpensesCaption | Annual Fund Operating Expenses (expenses that you pay each year as a percentage of the value of your investment) |
||||
Fee Waiver or Reimbursement over Assets, Date of Termination | rr_FeeWaiverOrReimbursementOverAssetsDateOfTermination | February 1, 2014 | ||||
Portfolio Turnover [Heading] | rr_PortfolioTurnoverHeading | Portfolio Turnover: | ||||
Portfolio Turnover [Text Block] | rr_PortfolioTurnoverTextBlock | The Fund pays transaction costs, such as commissions, when it buys and sells securities (or “turns over” its portfolio). A higher portfolio turnover may indicate higher transaction costs and may result in higher taxes when shares are held in a taxable account. These costs, which are not reflected in annual fund operating expenses or in the example, affect the Fund’s performance. During the most recent fiscal year, the Fund’s portfolio turnover rate was 99% of the average value of its portfolio. | ||||
Portfolio Turnover, Rate | rr_PortfolioTurnoverRate | 99.00% | ||||
Expenses Not Correlated to Ratio Due to Acquired Fund Fees [Text] | rr_ExpensesNotCorrelatedToRatioDueToAcquiredFundFees | The Total Annual Fund Operating Expenses do not correlate to the ratio of expenses to average net assets given in the Fund’s most recent annual report which does not include the Acquired Fund Fees and Expenses. | ||||
Expense Example [Heading] | rr_ExpenseExampleHeading | Example: | ||||
Expense Example Narrative [Text Block] | rr_ExpenseExampleNarrativeTextBlock | This Example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The Example assumes that you invest $10,000 in the Fund for the time periods indicated and then redeem all of your shares at the end of those periods. The Example also assumes that your investment has a 5% return each year and that the Fund’s operating expenses remain the same. Although your actual costs may be higher or lower, based on these assumptions your costs would be: | ||||
Strategy [Heading] | rr_StrategyHeading | Principal Investment Strategies of the Fund | ||||
Strategy Narrative [Text Block] | rr_StrategyNarrativeTextBlock | Under normal market conditions, International Opportunities invests at least 80% of its net assets in equity securities issued by foreign companies of any market capitalization. The Fund may invest up to 40% of its net assets in stocks of issuers in emerging market countries. The Fund seeks to buy primarily common stock but can also invest in preferred stock and convertible securities. From time to time the Fund may invest in shares of companies through initial public offerings (“IPOs”). The Fund may, when consistent with the Fund’s investment objective, buy or sell options or futures on a security or an index of securities and may buy options on a currency or a basket of currencies, or enter into foreign currency transactions, including swaps (collectively, commonly known as derivatives). The Fund typically uses derivatives as a substitute for taking a position in the underlying asset and/or as part of a strategy designed to reduce exposure to other risks, such as currency risk. The Fund may also use derivatives to enhance returns, in which case their use would involve leveraging risk. The Fund may seek to obtain market exposure to the securities in which it primarily invests by entering into a series of purchase and sale contracts or by using other investment techniques (such as reverse repurchase agreements or dollar rolls). The Fund may also use forward foreign currency exchange contracts (obligations to buy or sell a currency at a set rate in the future). |
||||
Risk [Heading] | rr_RiskHeading | Principal Risks of Investing in the Fund | ||||
Risk Narrative [Text Block] | rr_RiskNarrativeTextBlock | Risk is inherent in all investing. The value of your investment in International Opportunities, as well as the amount of return you receive on your investment, may fluctuate significantly from day to day and over time. You may lose part or all of your investment in the Fund or your investment may not perform as well as other similar investments. The following is a summary description of principal risks of investing in the Fund.
|
||||
Risk Lose Money [Text] | rr_RiskLoseMoney | You may lose part or all of your investment in the Fund or your investment may not perform as well as other similar investments. | ||||
Bar Chart and Performance Table [Heading] | rr_BarChartAndPerformanceTableHeading | Performance Information | ||||
Performance Narrative [Text Block] | rr_PerformanceNarrativeTextBlock | The information shows you how International Opportunities’ performance has varied year by year and provides some indication of the risks of investing in the Fund. The table compares the Fund’s performance to that of the MSCI All Country World Index Ex-U.S. As with all such investments, past performance (before and after taxes) is not an indication of future results. Sales charges are not reflected in the bar chart. If they were, returns would be less than those shown. However, the table includes all applicable fees and sales charges. If BlackRock and its affiliates had not waived or reimbursed certain Fund expenses during these periods, the Fund’s returns would have been lower. Updated information on the Fund’s results can be obtained by visiting http://www.blackrock.com/funds or can be obtained by phone at (800) 882-0052. | ||||
Performance Information Illustrates Variability of Returns [Text] | rr_PerformanceInformationIllustratesVariabilityOfReturns | The information shows you how International Opportunities’ performance has varied year by year and provides some indication of the risks of investing in the Fund. | ||||
Performance Availability Phone [Text] | rr_PerformanceAvailabilityPhone | (800) 882-0052 | ||||
Performance Availability Website Address [Text] | rr_PerformanceAvailabilityWebSiteAddress | http://www.blackrock.com/funds | ||||
Performance Past Does Not Indicate Future [Text] | rr_PerformancePastDoesNotIndicateFuture | As with all such investments, past performance (before and after taxes) is not an indication of future results. | ||||
Bar Chart [Heading] | rr_BarChartHeading | Service Shares ANNUAL TOTAL RETURNS BlackRock International Opportunities Portfolio As of 12/31 |
||||
Bar Chart Does Not Reflect Sales Loads [Text] | rr_BarChartDoesNotReflectSalesLoads | Sales charges are not reflected in the bar chart. If they were, returns would be less than those shown. | ||||
Bar Chart Closing [Text Block] | rr_BarChartClosingTextBlock | During the ten-year period shown in the bar chart, the highest return for a quarter was 28.04% (quarter ended June 30, 2009) and the lowest return for a quarter was –24.50% (quarter ended September 30, 2008). | ||||
Performance Table Heading | rr_PerformanceTableHeading | As of 12/31/12 Average Annual Total Returns |
||||
Performance Table Does Reflect Sales Loads | rr_PerformanceTableDoesReflectSalesLoads | However, the table includes all applicable fees and sales charges. | ||||
Performance Table Uses Highest Federal Rate | rr_PerformanceTableUsesHighestFederalRate | After-tax returns are calculated using the historical highest individual Federal marginal income tax rates and do not reflect the impact of state and local taxes. | ||||
Performance Table Not Relevant to Tax Deferred | rr_PerformanceTableNotRelevantToTaxDeferred | Actual after-tax returns depend on the investor’s tax situation and may differ from those shown, and the after-tax returns shown are not relevant to investors who hold their shares through tax-deferred arrangements such as 401(k) plans or individual retirement accounts. | ||||
Performance Table Narrative | rr_PerformanceTableNarrativeTextBlock | After-tax returns are calculated using the historical highest individual Federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on the investor’s tax situation and may differ from those shown, and the after-tax returns shown are not relevant to investors who hold their shares through tax-deferred arrangements such as 401(k) plans or individual retirement accounts. | ||||
Service Shares | BLACKROCK INTERNATIONAL OPPORTUNITIES PORTFOLIO | Service Shares
|
||||||
Risk/Return: | rr_RiskReturnAbstract | |||||
Management Fee | rr_ManagementFeesOverAssets | 0.98% | ||||
Distribution and/or Service (12b-1) Fees | rr_DistributionAndService12b1FeesOverAssets | 0.25% | ||||
Other Expenses | rr_OtherExpensesOverAssets | 0.67% | ||||
Acquired Fund Fees and Expenses | rr_AcquiredFundFeesAndExpensesOverAssets | 0.01% | [1] | |||
Total Annual Fund Operating Expenses | rr_ExpensesOverAssets | 1.91% | [1] | |||
Fee Waivers and/or Expense Reimbursements | rr_FeeWaiverOrReimbursementOverAssets | (0.10%) | [2] | |||
Total Annual Fund Operating Expenses After Fee Waivers and/or Expense Reimbursements | rr_NetExpensesOverAssets | 1.81% | [2] | |||
1 Year | rr_ExpenseExampleYear01 | 184 | ||||
3 Years | rr_ExpenseExampleYear03 | 590 | ||||
5 Years | rr_ExpenseExampleYear05 | 1,022 | ||||
10 Years | rr_ExpenseExampleYear10 | 2,225 | ||||
2003 | rr_AnnualReturn2003 | 48.82% | ||||
2004 | rr_AnnualReturn2004 | 23.70% | ||||
2005 | rr_AnnualReturn2005 | 31.83% | ||||
2006 | rr_AnnualReturn2006 | 31.55% | ||||
2007 | rr_AnnualReturn2007 | 18.12% | ||||
2008 | rr_AnnualReturn2008 | (43.33%) | ||||
2009 | rr_AnnualReturn2009 | 36.52% | ||||
2010 | rr_AnnualReturn2010 | 11.25% | ||||
2011 | rr_AnnualReturn2011 | (14.53%) | ||||
2012 | rr_AnnualReturn2012 | 17.77% | ||||
Highest Quarterly Return, Label | rr_HighestQuarterlyReturnLabel | highest return | ||||
Highest Quarterly Return, Date | rr_BarChartHighestQuarterlyReturnDate | Jun. 30, 2009 | ||||
Highest Quarterly Return | rr_BarChartHighestQuarterlyReturn | 28.04% | ||||
Lowest Quarterly Return, Label | rr_LowestQuarterlyReturnLabel | lowest return | ||||
Lowest Quarterly Return, Date | rr_BarChartLowestQuarterlyReturnDate | Sep. 30, 2008 | ||||
Lowest Quarterly Return | rr_BarChartLowestQuarterlyReturn | (24.50%) | ||||
1 Year | rr_AverageAnnualReturnYear01 | 17.77% | ||||
5 Years | rr_AverageAnnualReturnYear05 | (2.83%) | ||||
10 Years | rr_AverageAnnualReturnYear10 | 12.57% | ||||
Service Shares | BLACKROCK INTERNATIONAL OPPORTUNITIES PORTFOLIO | Return After Taxes on Distributions | Service Shares
|
||||||
Risk/Return: | rr_RiskReturnAbstract | |||||
1 Year | rr_AverageAnnualReturnYear01 | 17.56% | ||||
5 Years | rr_AverageAnnualReturnYear05 | (2.91%) | ||||
10 Years | rr_AverageAnnualReturnYear10 | 11.75% | ||||
Service Shares | BLACKROCK INTERNATIONAL OPPORTUNITIES PORTFOLIO | Return After Taxes on Distributions and Sale of Shares | Service Shares
|
||||||
Risk/Return: | rr_RiskReturnAbstract | |||||
1 Year | rr_AverageAnnualReturnYear01 | 11.82% | ||||
5 Years | rr_AverageAnnualReturnYear05 | (2.35%) | ||||
10 Years | rr_AverageAnnualReturnYear10 | 11.19% | ||||
Service Shares | BLACKROCK INTERNATIONAL OPPORTUNITIES PORTFOLIO | MSCI All Country World Index Ex-U.S (Reflects no deduction for fees, expenses or taxes)
|
||||||
Risk/Return: | rr_RiskReturnAbstract | |||||
1 Year | rr_AverageAnnualReturnYear01 | 16.83% | ||||
5 Years | rr_AverageAnnualReturnYear05 | (2.89%) | ||||
10 Years | rr_AverageAnnualReturnYear10 | 9.74% | ||||
|
Service Shares | BLACKROCK SCIENCE & TECHNOLOGY OPPORTUNITIES PORTFOLIO | ||||||||||||||||||||||||||||||||
Fund Overview Key Facts About BlackRock Science & Technology Opportunities Portfolio |
||||||||||||||||||||||||||||||||
Investment Objective | ||||||||||||||||||||||||||||||||
The investment objective of BlackRock Science & Technology Opportunities Portfolio (“Science & Technology Opportunities” or the “Fund”), a series of BlackRock FundsSM (the “Trust”), is to provide long-term capital appreciation. | ||||||||||||||||||||||||||||||||
Fees and Expenses of the Fund | ||||||||||||||||||||||||||||||||
This table describes the fees and expenses that you may pay if you buy and hold Services Shares of Science & Technology Opportunities. | ||||||||||||||||||||||||||||||||
Annual Fund Operating Expenses (expenses that you pay each year as a percentage of the value of your investment) |
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
Example: | ||||||||||||||||||||||||||||||||
This Example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The Example assumes that you invest $10,000 in the Fund for the time periods indicated and then redeem all of your shares at the end of those periods. The Example also assumes that your investment has a 5% return each year and that the Fund’s operating expenses remain the same. Although your actual costs may be higher or lower, based on these assumptions your costs would be: | ||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
Portfolio Turnover: | ||||||||||||||||||||||||||||||||
The Fund pays transaction costs, such as commissions, when it buys and sells securities (or “turns over” its portfolio). A higher portfolio turnover may indicate higher transaction costs and may result in higher taxes when shares are held in a taxable account. These costs, which are not reflected in annual fund operating expenses or in the example, affect the Fund’s performance. During the most recent fiscal year, the Fund’s portfolio turnover rate was 320% of the average value of its portfolio. | ||||||||||||||||||||||||||||||||
Principal Investment Strategies of the Fund | ||||||||||||||||||||||||||||||||
Under normal market conditions, Science & Technology Opportunities invests at least 80% of its net assets in equity securities issued by U.S. and non-U.S. science and technology companies in all market capitalization ranges, selected for their rapid and sustainable growth potential from the development, advancement and use of science and/or use of technology. The Fund may invest up to 25% of its net assets in emerging market countries. Some of the industries likely to be represented in the Fund’s portfolio holdings include: application software, IT consulting and services, internet software and services, networking equipment, telecom equipment, computer hardware, computer storage and peripherals, electronic equipment and instruments, semiconductors and equipment, aerospace and defense, electrical components and equipment, biotechnology, pharmaceuticals, healthcare equipment and supplies, healthcare distribution and services, healthcare facilities, industrial gases, specialty chemicals, advanced materials, internet and catalog retail, integrated telecom services, alternative carriers and wireless telecommunication services. The Fund seeks to invest primarily in common stock but may also invest in preferred stock and convertible securities. The Fund may also invest in Rule 144A securities, which are privately placed securities purchased by qualified institutional buyers. From time to time the Fund may invest in shares of companies through initial public offerings (“IPOs”). The Fund may, when consistent with the Fund’s investment objective, buy or sell options or futures on a security or an index of securities and may buy options on a currency or a basket of currencies, or enter into foreign currency transactions, including swaps (collectively, commonly known as derivatives). The Fund typically uses derivatives as a substitute for taking a position in the underlying asset and/or as part of a strategy designed to reduce exposure to other risks, such as currency risk. The Fund may also use derivatives to enhance returns, in which case their use would involve leveraging risk. The Fund may seek to obtain market exposure to the securities in which it primarily invests by entering into a series of purchase and sale contracts or by using other investment techniques (such as reverse repurchase agreements or dollar rolls). The Fund may also use forward foreign currency exchange contracts (obligations to buy or sell a currency at a set rate in the future). |
||||||||||||||||||||||||||||||||
Principal Risks of Investing in the Fund | ||||||||||||||||||||||||||||||||
Risk is inherent in all investing. The value of your investment in Science & Technology Opportunities, as well as the amount of return you receive on your investment, may fluctuate significantly from day to day and over time. You may lose part or all of your investment in the Fund or your investment may not perform as well as other similar investments. The following is a summary description of principal risks of investing in the Fund.
|
||||||||||||||||||||||||||||||||
Performance Information | ||||||||||||||||||||||||||||||||
The information shows you how Science & Technology Opportunities’ performance has varied year by year and provides some indication of the risks of investing in the Fund. The table compares the Fund’s performance to that of the NYSE Arca Tech 100 IndexSM. As with all such investments, past performance (before and after taxes) is not an indication of future results. Sales charges are not reflected in the bar chart. If they were, returns would be less than those shown. However, the table includes all applicable fees and sales charges. If BlackRock and its affiliates had not waived or reimbursed certain Fund expenses during these periods, the Fund’s returns would have been lower. Updated information on the Fund’s results can be obtained by visiting http://www.blackrock.com/funds or can be obtained by phone at (800) 882-0052. | ||||||||||||||||||||||||||||||||
Service Shares ANNUAL TOTAL RETURNS BlackRock Science & Technology Opportunities Portfolio As of 12/31 |
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
During the ten-year period shown in the bar chart, the highest return for a quarter was 30.03% (quarter ended June 30, 2003) and the lowest return for a quarter was –22.21% (quarter ended December 31, 2008). | ||||||||||||||||||||||||||||||||
As of 12/31/12 Average Annual Total Returns |
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
After-tax returns are calculated using the historical highest individual Federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on the investor’s tax situation and may differ from those shown, and the after-tax returns shown are not relevant to investors who hold their shares through tax-deferred arrangements such as 401(k) plans or individual retirement accounts. |
Label | Element | Value | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Risk/Return: | rr_RiskReturnAbstract | |||||||||||||
Registrant Name | dei_EntityRegistrantName | BLACKROCK FUNDS | ||||||||||||
Prospectus Date | rr_ProspectusDate | Jan. 28, 2013 | ||||||||||||
Investor, Institutional and R Shares | BLACKROCK SCIENCE & TECHNOLOGY OPPORTUNITIES PORTFOLIO
|
||||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||||
Risk/Return [Heading] | rr_RiskReturnHeading | Fund Overview Key Facts About BlackRock Science & Technology Opportunities Portfolio |
||||||||||||
Objective [Heading] | rr_ObjectiveHeading | Investment Objective | ||||||||||||
Objective, Primary [Text Block] | rr_ObjectivePrimaryTextBlock | The investment objective of BlackRock Science & Technology Opportunities Portfolio (“Science & Technology Opportunities” or the “Fund”), a series of BlackRock FundsSM (the “Trust”), is to provide long-term capital appreciation. | ||||||||||||
Expense [Heading] | rr_ExpenseHeading | Fees and Expenses of the Fund | ||||||||||||
Expense Narrative [Text Block] | rr_ExpenseNarrativeTextBlock | This table describes the fees and expenses that you may pay if you buy and hold shares of Science & Technology Opportunities. You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $25,000 in the fund complex advised by BlackRock Advisors, LLC (“BlackRock”). More information about these and other discounts is available from your financial professional and in the “Details About the Share Classes” section on page 47 of the Fund’s prospectus and in the “Purchase of Shares” section on page II-58 of the Fund’s statement of additional information. | ||||||||||||
Shareholder Fees Caption [Text] | rr_ShareholderFeesCaption | Shareholder Fees (fees paid directly from your investment) |
||||||||||||
Operating Expenses Caption [Text] | rr_OperatingExpensesCaption | Annual Fund Operating Expenses (expenses that are deducted from Fund assets) |
||||||||||||
Fee Waiver or Reimbursement over Assets, Date of Termination | rr_FeeWaiverOrReimbursementOverAssetsDateOfTermination | February 1, 2014 | ||||||||||||
Portfolio Turnover [Heading] | rr_PortfolioTurnoverHeading | Portfolio Turnover: | ||||||||||||
Portfolio Turnover [Text Block] | rr_PortfolioTurnoverTextBlock | The Fund pays transaction costs, such as commissions, when it buys and sells securities (or “turns over” its portfolio). A higher portfolio turnover may indicate higher transaction costs and may result in higher taxes when shares are held in a taxable account. These costs, which are not reflected in annual fund operating expenses or in the example, affect the Fund’s performance. During the most recent fiscal year, the Fund’s portfolio turnover rate was 320% of the average value of its portfolio. | ||||||||||||
Portfolio Turnover, Rate | rr_PortfolioTurnoverRate | 320.00% | ||||||||||||
Expenses Deferred Charges [Text Block] | rr_ExpensesDeferredChargesTextBlock | A contingent deferred sales charge ("CDSC") of 1.00% is assessed on certain redemptions of Investor A Shares made within 18 months after purchase where no initial sales charge was paid at time of purchase as part of an investment of $1,000,000 or more. | ||||||||||||
Expense Breakpoint Discounts [Text] | rr_ExpenseBreakpointDiscounts | You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $25,000 in the fund complex advised by BlackRock Advisors, LLC (“BlackRock”). | ||||||||||||
Expense Breakpoint, Minimum Investment Required [Amount] | rr_ExpenseBreakpointMinimumInvestmentRequiredAmount | 25,000 | ||||||||||||
Expenses Not Correlated to Ratio Due to Acquired Fund Fees [Text] | rr_ExpensesNotCorrelatedToRatioDueToAcquiredFundFees | The Total Annual Fund Operating Expenses do not correlate to the ratio of expenses to average net assets given in the Fund's most recent annual report which does not include the Acquired Fund Fees and Expenses. | ||||||||||||
Expense Example [Heading] | rr_ExpenseExampleHeading | Example: | ||||||||||||
Expense Example Narrative [Text Block] | rr_ExpenseExampleNarrativeTextBlock | This Example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The Example assumes that you invest $10,000 in the Fund for the time periods indicated and then redeem all of your shares at the end of those periods. The Example also assumes that your investment has a 5% return each year and that the Fund’s operating expenses remain the same. Although your actual costs may be higher or lower, based on these assumptions your costs would be: | ||||||||||||
Expense Example, No Redemption, By Year, Caption [Text] | rr_ExpenseExampleNoRedemptionByYearCaption | You would pay the following expenses if you did not redeem your shares: | ||||||||||||
Strategy [Heading] | rr_StrategyHeading | Principal Investment Strategies of the Fund | ||||||||||||
Strategy Narrative [Text Block] | rr_StrategyNarrativeTextBlock | Under normal market conditions, Science & Technology Opportunities invests at least 80% of its net assets in equity securities issued by U.S. and non-U.S. science and technology companies in all market capitalization ranges, selected for their rapid and sustainable growth potential from the development, advancement and use of science and/or use of technology. The Fund may invest up to 25% of its net assets in emerging market countries. Some of the industries likely to be represented in the Fund’s portfolio holdings include: application software, IT consulting and services, internet software and services, networking equipment, telecom equipment, computer hardware, computer storage and peripherals, electronic equipment and instruments, semiconductors and equipment, aerospace and defense, electrical components and equipment, biotechnology, pharmaceuticals, healthcare equipment and supplies, healthcare distribution and services, healthcare facilities, industrial gases, specialty chemicals, advanced materials, internet and catalog retail, integrated telecom services, alternative carriers and wireless telecommunication services. The Fund seeks to invest primarily in common stock but may also invest in preferred stock and convertible securities. The Fund may also invest in Rule 144A securities, which are privately placed securities purchased by qualified institutional buyers. From time to time the Fund may invest in shares of companies through initial public offerings (“IPOs”). The Fund may, when consistent with the Fund’s investment objective, buy or sell options or futures on a security or an index of securities and may buy options on a currency or a basket of currencies, or enter into foreign currency transactions, including swaps (collectively, commonly known as derivatives). The Fund typically uses derivatives as a substitute for taking a position in the underlying asset and/or as part of a strategy designed to reduce exposure to other risks, such as currency risk. The Fund may also use derivatives to enhance returns, in which case their use would involve leveraging risk. The Fund may seek to obtain market exposure to the securities in which it primarily invests by entering into a series of purchase and sale contracts or by using other investment techniques (such as reverse repurchase agreements or dollar rolls). The Fund may also use forward foreign currency exchange contracts (obligations to buy or sell a currency at a set rate in the future). |
||||||||||||
Risk [Heading] | rr_RiskHeading | Principal Risks of Investing in the Fund | ||||||||||||
Risk Narrative [Text Block] | rr_RiskNarrativeTextBlock | Risk is inherent in all investing. The value of your investment in Science & Technology Opportunities, as well as the amount of return you receive on your investment, may fluctuate significantly from day to day and over time. You may lose part or all of your investment in the Fund or your investment may not perform as well as other similar investments. The following is a summary description of principal risks of investing in the Fund.
|
||||||||||||
Risk Lose Money [Text] | rr_RiskLoseMoney | You may lose part or all of your investment in the Fund or your investment may not perform as well as other similar investments. | ||||||||||||
Bar Chart and Performance Table [Heading] | rr_BarChartAndPerformanceTableHeading | Performance Information | ||||||||||||
Performance Narrative [Text Block] | rr_PerformanceNarrativeTextBlock | The information shows you how Science & Technology Opportunities’ performance has varied year by year and provides some indication of the risks of investing in the Fund. The table compares the Fund’s performance to that of the NYSE Arca Tech 100 IndexSM. The returns for Class R Shares prior to October 2, 2006, the commencement of operations of Class R Shares, are based upon performance of the Fund’s Institutional Shares. The returns for Class R Shares, however, are adjusted to reflect the class-specific fees applicable to Class R Shares at the time of such share class’ launch. As with all such investments, past performance (before and after taxes) is not an indication of future results. Sales charges are not reflected in the bar chart. If they were, returns would be less than those shown. However, the table includes all applicable fees and sales charges. If BlackRock and its affiliates had not waived or reimbursed certain Fund expenses during these periods, the Fund’s returns would have been lower. Updated information on the Fund’s results can be obtained by visiting http://www.blackrock.com/funds or can be obtained by phone at (800) 882-0052. | ||||||||||||
Performance Information Illustrates Variability of Returns [Text] | rr_PerformanceInformationIllustratesVariabilityOfReturns | The information shows you how Science & Technology Opportunities’ performance has varied year by year and provides some indication of the risks of investing in the Fund. | ||||||||||||
Performance Availability Phone [Text] | rr_PerformanceAvailabilityPhone | (800) 882-0052 | ||||||||||||
Performance Availability Website Address [Text] | rr_PerformanceAvailabilityWebSiteAddress | http://www.blackrock.com/funds | ||||||||||||
Performance Past Does Not Indicate Future [Text] | rr_PerformancePastDoesNotIndicateFuture | As with all such investments, past performance (before and after taxes) is not an indication of future results. | ||||||||||||
Bar Chart [Heading] | rr_BarChartHeading | Investor A Shares ANNUAL TOTAL RETURNS BlackRock Science & Technology Opportunities Portfolio As of 12/31 |
||||||||||||
Bar Chart Does Not Reflect Sales Loads [Text] | rr_BarChartDoesNotReflectSalesLoads | Sales charges are not reflected in the bar chart. If they were, returns would be less than those shown. | ||||||||||||
Bar Chart Closing [Text Block] | rr_BarChartClosingTextBlock | During the periods shown in the bar chart, the highest return for a quarter was 29.92% (quarter ended June 30, 2003) and the lowest return for a quarter was –22.29% (quarter ended December 31, 2008). | ||||||||||||
Performance Table Heading | rr_PerformanceTableHeading | As of 12/31/12 Average Annual Total Returns |
||||||||||||
Performance Table Does Reflect Sales Loads | rr_PerformanceTableDoesReflectSalesLoads | However, the table includes all applicable fees and sales charges. | ||||||||||||
Performance Table Uses Highest Federal Rate | rr_PerformanceTableUsesHighestFederalRate | After-tax returns are calculated using the historical highest individual Federal marginal income tax rates and do not reflect the impact of state and local taxes. | ||||||||||||
Performance Table Not Relevant to Tax Deferred | rr_PerformanceTableNotRelevantToTaxDeferred | Actual after-tax returns depend on the investor’s tax situation and may differ from those shown, and the after-tax returns shown are not relevant to investors who hold their shares through tax-deferred arrangements such as 401(k) plans or individual retirement accounts. | ||||||||||||
Performance Table One Class of after Tax Shown [Text] | rr_PerformanceTableOneClassOfAfterTaxShown | After-tax returns are shown for Investor A Shares only, and the after-tax returns for Investor B, Investor C, Institutional and Class R Shares will vary. | ||||||||||||
Performance Table Narrative | rr_PerformanceTableNarrativeTextBlock | After-tax returns are calculated using the historical highest individual Federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on the investor’s tax situation and may differ from those shown, and the after-tax returns shown are not relevant to investors who hold their shares through tax-deferred arrangements such as 401(k) plans or individual retirement accounts. After-tax returns are shown for Investor A Shares only, and the after-tax returns for Investor B, Investor C, Institutional and Class R Shares will vary. | ||||||||||||
Investor, Institutional and R Shares | BLACKROCK SCIENCE & TECHNOLOGY OPPORTUNITIES PORTFOLIO | Investor A Shares
|
||||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||||
Maximum Sales Charge (Load) Imposed on Purchases (as percentage of offering price) | rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice | 5.25% | ||||||||||||
Maximum Deferred Sales Charge (Load) (as percentage of offering price or redemption proceeds, whichever is lower) | rr_MaximumDeferredSalesChargeOverOfferingPrice | none | [1] | |||||||||||
Management Fees | rr_ManagementFeesOverAssets | 0.90% | ||||||||||||
Distribution (12b-1) and/or Service Fees | rr_DistributionAndService12b1FeesOverAssets | 0.25% | ||||||||||||
Other Expenses | rr_OtherExpensesOverAssets | 0.57% | ||||||||||||
Acquired Fund Fees and Expenses | rr_AcquiredFundFeesAndExpensesOverAssets | 0.01% | [2] | |||||||||||
Total Annual Fund Operating Expenses | rr_ExpensesOverAssets | 1.73% | [2] | |||||||||||
Fee Waivers and/or Expense Reimbursements | rr_FeeWaiverOrReimbursementOverAssets | [3] | ||||||||||||
Total Annual Fund Operating Expenses After Fee Waivers and/or Expense Reimbursements | rr_NetExpensesOverAssets | 1.73% | [3] | |||||||||||
1 Year | rr_ExpenseExampleYear01 | 692 | ||||||||||||
3 Years | rr_ExpenseExampleYear03 | 1,041 | ||||||||||||
5 Years | rr_ExpenseExampleYear05 | 1,414 | ||||||||||||
10 Years | rr_ExpenseExampleYear10 | 2,459 | ||||||||||||
2003 | rr_AnnualReturn2003 | 58.36% | ||||||||||||
2004 | rr_AnnualReturn2004 | 2.18% | ||||||||||||
2005 | rr_AnnualReturn2005 | 11.15% | ||||||||||||
2006 | rr_AnnualReturn2006 | 7.67% | ||||||||||||
2007 | rr_AnnualReturn2007 | 19.18% | ||||||||||||
2008 | rr_AnnualReturn2008 | (39.89%) | ||||||||||||
2009 | rr_AnnualReturn2009 | 56.21% | [4] | |||||||||||
2010 | rr_AnnualReturn2010 | 17.99% | ||||||||||||
2011 | rr_AnnualReturn2011 | (11.31%) | ||||||||||||
2012 | rr_AnnualReturn2012 | 7.25% | ||||||||||||
Highest Quarterly Return, Label | rr_HighestQuarterlyReturnLabel | highest return | ||||||||||||
Highest Quarterly Return, Date | rr_BarChartHighestQuarterlyReturnDate | Jun. 30, 2003 | ||||||||||||
Highest Quarterly Return | rr_BarChartHighestQuarterlyReturn | 29.92% | ||||||||||||
Lowest Quarterly Return, Label | rr_LowestQuarterlyReturnLabel | lowest return | ||||||||||||
Lowest Quarterly Return, Date | rr_BarChartLowestQuarterlyReturnDate | Dec. 31, 2008 | ||||||||||||
Lowest Quarterly Return | rr_BarChartLowestQuarterlyReturn | (22.29%) | ||||||||||||
1 Year | rr_AverageAnnualReturnYear01 | 1.66% | ||||||||||||
5 Years | rr_AverageAnnualReturnYear05 | (0.02%) | [4] | |||||||||||
10 Years | rr_AverageAnnualReturnYear10 | 8.70% | [4] | |||||||||||
Investor, Institutional and R Shares | BLACKROCK SCIENCE & TECHNOLOGY OPPORTUNITIES PORTFOLIO | Investor B Shares
|
||||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||||
Maximum Sales Charge (Load) Imposed on Purchases (as percentage of offering price) | rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice | none | ||||||||||||
Maximum Deferred Sales Charge (Load) (as percentage of offering price or redemption proceeds, whichever is lower) | rr_MaximumDeferredSalesChargeOverOfferingPrice | 4.50% | [5] | |||||||||||
Management Fees | rr_ManagementFeesOverAssets | 0.90% | ||||||||||||
Distribution (12b-1) and/or Service Fees | rr_DistributionAndService12b1FeesOverAssets | 1.00% | ||||||||||||
Other Expenses | rr_OtherExpensesOverAssets | 0.62% | ||||||||||||
Acquired Fund Fees and Expenses | rr_AcquiredFundFeesAndExpensesOverAssets | 0.01% | [2] | |||||||||||
Total Annual Fund Operating Expenses | rr_ExpensesOverAssets | 2.53% | [2] | |||||||||||
Fee Waivers and/or Expense Reimbursements | rr_FeeWaiverOrReimbursementOverAssets | [3] | ||||||||||||
Total Annual Fund Operating Expenses After Fee Waivers and/or Expense Reimbursements | rr_NetExpensesOverAssets | 2.53% | [3] | |||||||||||
1 Year | rr_ExpenseExampleYear01 | 706 | ||||||||||||
3 Years | rr_ExpenseExampleYear03 | 1,138 | ||||||||||||
5 Years | rr_ExpenseExampleYear05 | 1,545 | ||||||||||||
10 Years | rr_ExpenseExampleYear10 | 2,670 | ||||||||||||
1 Year | rr_ExpenseExampleNoRedemptionYear01 | 256 | ||||||||||||
3 Years | rr_ExpenseExampleNoRedemptionYear03 | 788 | ||||||||||||
5 Years | rr_ExpenseExampleNoRedemptionYear05 | 1,345 | ||||||||||||
10 Years | rr_ExpenseExampleNoRedemptionYear10 | 2,670 | ||||||||||||
1 Year | rr_AverageAnnualReturnYear01 | 1.94% | ||||||||||||
5 Years | rr_AverageAnnualReturnYear05 | (0.23%) | [4] | |||||||||||
10 Years | rr_AverageAnnualReturnYear10 | 8.57% | [4] | |||||||||||
Investor, Institutional and R Shares | BLACKROCK SCIENCE & TECHNOLOGY OPPORTUNITIES PORTFOLIO | Investor C Shares
|
||||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||||
Maximum Sales Charge (Load) Imposed on Purchases (as percentage of offering price) | rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice | none | ||||||||||||
Maximum Deferred Sales Charge (Load) (as percentage of offering price or redemption proceeds, whichever is lower) | rr_MaximumDeferredSalesChargeOverOfferingPrice | 1.00% | [6] | |||||||||||
Management Fees | rr_ManagementFeesOverAssets | 0.90% | ||||||||||||
Distribution (12b-1) and/or Service Fees | rr_DistributionAndService12b1FeesOverAssets | 1.00% | ||||||||||||
Other Expenses | rr_OtherExpensesOverAssets | 0.70% | ||||||||||||
Acquired Fund Fees and Expenses | rr_AcquiredFundFeesAndExpensesOverAssets | 0.01% | [2] | |||||||||||
Total Annual Fund Operating Expenses | rr_ExpensesOverAssets | 2.61% | [2] | |||||||||||
Fee Waivers and/or Expense Reimbursements | rr_FeeWaiverOrReimbursementOverAssets | [3] | ||||||||||||
Total Annual Fund Operating Expenses After Fee Waivers and/or Expense Reimbursements | rr_NetExpensesOverAssets | 2.61% | [3] | |||||||||||
1 Year | rr_ExpenseExampleYear01 | 364 | ||||||||||||
3 Years | rr_ExpenseExampleYear03 | 811 | ||||||||||||
5 Years | rr_ExpenseExampleYear05 | 1,385 | ||||||||||||
10 Years | rr_ExpenseExampleYear10 | 2,944 | ||||||||||||
1 Year | rr_ExpenseExampleNoRedemptionYear01 | 264 | ||||||||||||
3 Years | rr_ExpenseExampleNoRedemptionYear03 | 811 | ||||||||||||
5 Years | rr_ExpenseExampleNoRedemptionYear05 | 1,385 | ||||||||||||
10 Years | rr_ExpenseExampleNoRedemptionYear10 | 2,944 | ||||||||||||
1 Year | rr_AverageAnnualReturnYear01 | 5.31% | ||||||||||||
5 Years | rr_AverageAnnualReturnYear05 | 0.17% | [4] | |||||||||||
10 Years | rr_AverageAnnualReturnYear10 | 8.36% | [4] | |||||||||||
Investor, Institutional and R Shares | BLACKROCK SCIENCE & TECHNOLOGY OPPORTUNITIES PORTFOLIO | Institutional Shares
|
||||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||||
Maximum Sales Charge (Load) Imposed on Purchases (as percentage of offering price) | rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice | none | ||||||||||||
Maximum Deferred Sales Charge (Load) (as percentage of offering price or redemption proceeds, whichever is lower) | rr_MaximumDeferredSalesChargeOverOfferingPrice | none | ||||||||||||
Management Fees | rr_ManagementFeesOverAssets | 0.90% | ||||||||||||
Distribution (12b-1) and/or Service Fees | rr_DistributionAndService12b1FeesOverAssets | none | ||||||||||||
Other Expenses | rr_OtherExpensesOverAssets | 0.55% | ||||||||||||
Acquired Fund Fees and Expenses | rr_AcquiredFundFeesAndExpensesOverAssets | 0.01% | [2] | |||||||||||
Total Annual Fund Operating Expenses | rr_ExpensesOverAssets | 1.46% | [2] | |||||||||||
Fee Waivers and/or Expense Reimbursements | rr_FeeWaiverOrReimbursementOverAssets | (0.06%) | [3] | |||||||||||
Total Annual Fund Operating Expenses After Fee Waivers and/or Expense Reimbursements | rr_NetExpensesOverAssets | 1.40% | [3] | |||||||||||
1 Year | rr_ExpenseExampleYear01 | 143 | ||||||||||||
3 Years | rr_ExpenseExampleYear03 | 456 | ||||||||||||
5 Years | rr_ExpenseExampleYear05 | 792 | ||||||||||||
10 Years | rr_ExpenseExampleYear10 | 1,741 | ||||||||||||
1 Year | rr_AverageAnnualReturnYear01 | 7.57% | ||||||||||||
5 Years | rr_AverageAnnualReturnYear05 | 1.43% | [4] | |||||||||||
10 Years | rr_AverageAnnualReturnYear10 | 9.72% | [4] | |||||||||||
Investor, Institutional and R Shares | BLACKROCK SCIENCE & TECHNOLOGY OPPORTUNITIES PORTFOLIO | Class R Shares
|
||||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||||
Maximum Sales Charge (Load) Imposed on Purchases (as percentage of offering price) | rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice | none | ||||||||||||
Maximum Deferred Sales Charge (Load) (as percentage of offering price or redemption proceeds, whichever is lower) | rr_MaximumDeferredSalesChargeOverOfferingPrice | none | ||||||||||||
Management Fees | rr_ManagementFeesOverAssets | 0.90% | ||||||||||||
Distribution (12b-1) and/or Service Fees | rr_DistributionAndService12b1FeesOverAssets | 0.50% | ||||||||||||
Other Expenses | rr_OtherExpensesOverAssets | 0.60% | ||||||||||||
Acquired Fund Fees and Expenses | rr_AcquiredFundFeesAndExpensesOverAssets | 0.01% | [2] | |||||||||||
Total Annual Fund Operating Expenses | rr_ExpensesOverAssets | 2.01% | [2] | |||||||||||
Fee Waivers and/or Expense Reimbursements | rr_FeeWaiverOrReimbursementOverAssets | [3] | ||||||||||||
Total Annual Fund Operating Expenses After Fee Waivers and/or Expense Reimbursements | rr_NetExpensesOverAssets | 2.01% | [3] | |||||||||||
1 Year | rr_ExpenseExampleYear01 | 204 | ||||||||||||
3 Years | rr_ExpenseExampleYear03 | 630 | ||||||||||||
5 Years | rr_ExpenseExampleYear05 | 1,083 | ||||||||||||
10 Years | rr_ExpenseExampleYear10 | 2,338 | ||||||||||||
1 Year | rr_AverageAnnualReturnYear01 | 6.96% | ||||||||||||
5 Years | rr_AverageAnnualReturnYear05 | 0.72% | [4] | |||||||||||
10 Years | rr_AverageAnnualReturnYear10 | 8.92% | [4] | |||||||||||
Investor, Institutional and R Shares | BLACKROCK SCIENCE & TECHNOLOGY OPPORTUNITIES PORTFOLIO | Return After Taxes on Distributions | Investor A Shares
|
||||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||||
1 Year | rr_AverageAnnualReturnYear01 | 1.66% | ||||||||||||
5 Years | rr_AverageAnnualReturnYear05 | (0.02%) | [4] | |||||||||||
10 Years | rr_AverageAnnualReturnYear10 | 8.70% | [4] | |||||||||||
Investor, Institutional and R Shares | BLACKROCK SCIENCE & TECHNOLOGY OPPORTUNITIES PORTFOLIO | Return After Taxes on Distributions and Sale of Shares | Investor A Shares
|
||||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||||
1 Year | rr_AverageAnnualReturnYear01 | 1.08% | ||||||||||||
5 Years | rr_AverageAnnualReturnYear05 | (0.02%) | [4] | |||||||||||
10 Years | rr_AverageAnnualReturnYear10 | 7.74% | [4] | |||||||||||
Investor, Institutional and R Shares | BLACKROCK SCIENCE & TECHNOLOGY OPPORTUNITIES PORTFOLIO | NYSE Arca Tech 100 Index℠ (Reflects no deduction for fees, expenses or taxes)
|
||||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||||
1 Year | rr_AverageAnnualReturnYear01 | 21.46% | ||||||||||||
5 Years | rr_AverageAnnualReturnYear05 | 7.62% | [4] | |||||||||||
10 Years | rr_AverageAnnualReturnYear10 | 11.69% | [4] | |||||||||||
|
'///0\[\,5F7PM*MU)'+<#5-3$CQH41F^W3 MY*J2Q4$]`2<>IZUQ=3W.AU5?'_[8/_)2],_[!$7_`*.FK[!KX_\`VP?^2EZ9 M_P!@B+_T=-4U-BZ7Q'TW\+_^29^$O^P1:?\`HE*Z>N9^%W_),_"/_8(M/_1* M5T^*I;$O<\KT:WA35]`U5(8UU2]\3:K9W-X%`FG@3[?LB=_O,B^3%A22!Y:8 M'RC'J=48=&TR'5Y]5ATZSCU2=!'+>)`HFD7CY6?&XCY5X)_A'I5_%)*P/4Q= M8N-?BN571M,TJ[M]@+/=ZC);N&R<@*L$@(QCG(ZGCC)X_P"'-WXL7X>^%UM= M$T*6W&EVHC>36)4=E\I<%E%JP4D=0"<>IZUZ5BN8^%W_`"3/PC_V"+3_`-$I M1U#HMOL4$\.S^UIGW^:T1SG[*,8\KWSN[8Y@M_"W MC.''^@>'C_W%9A_[;5ZUBC%7& '?"GC+1O%$>L?8?#TVRSFM?)_M69<^8\3;MWV8]/*QC'\7MSZWBC%$I MRENQ4\/3IN\5^9R_VWQE_P!`#P]_X.YO_D2C[;XR_P"@!X>_\' 6>+_#OC+Q%J^EWW]G>'K;[##/#L_M:9]_FM$ '?"GC+1O%$>L?8?#TVRSFM?)_M69<^8\3;MWV8]/*QC'\7MS MZWBC%$IRENQ4\/3IN\5^9R_VWQE_T`/#W_@[F_\`D2C[;XR_Z`'A[_P=S?\` MR)748HQ4FYY9XP\.^,O$>KZ7??V=X>MOL4,\.S^UIGW^:T1SG[,,8\KWSN[8 MY@M_"OC.''^@^'C_`-Q68?\`MM7K6*,549RCLS&I0IU'>2_,\GN/#'C.;/\` MH'AY?^XK,?\`VVIGAWPKXRT?Q1'K'V'P]-LLYK3R?[5F7/F/$V[=]F/3RL8Q M_%[<^MXHQ3E.4MV*GAZ=-WBOS.7^V^,O^@!X>_\`!W-_\B4?;?&7_0`\/?\` M@[F_^1*ZC%&*@W/+/&'AWQEXCU?2[[^SO#UM]BAGAV?VM,^_S6B.<_9AC'E> M^=W;',%MX5\9PX_T'P\W_<5F'_MM7K6*,549RCLS&I0IU'>2_,\GN/#'C.;/ M^@>'A_W%9C_[;4SP[X5\9:/XHCUC[#X>FV6 KZ7??V=X>MOL4,\.S^UIGW^:T1SG[,,8\K MWSN[8YKV_A7QG#C_`$'P\W_<5F'_`+;5ZWBC%5& '_<5F_^1J9X>\*^,M'\41ZQ]A\/3;+.:T\G^U9ESYCQ-NW?9CT\ MK&,?Q>W/K6*,4Y3E+=BIX>G3=XK\SE_MOC+_`*`'A[_P=S?_`")1]M\9?]`# MP]_X.YO_`)$KJ,48J#<\W\1>-_$N@ZE86-YX;T=Y;V*:6,Q:S*5`C,8;.;4< M_O5QUZ'IW6V\;>);C&SPWHX^NLR__(M4?BW_`,CCX7_Z\K__`-&6E+H_:O#Q MN.K4:SA!Z'TF799A\1AE5FM;OJ:-QXQ\36_W_#FBGZ:S+_\`(M5M)\>^(]4U M]-(M_#>D+ 'HX6=6"U5NOFCN?MOC+_H`>'O\`P=S?_(E'VWQE M_P!`#P]_X.YO_D2NHQ1BO>/F3ROQAX<\9>(]7TN^_L[P];?8H9X=G]K3/O\` M-:(YS]F&,>5[YW=L MXHQ51G*.S,:E"G4=Y+ M\SRBX\,>,YO^7#P\/^XK-_\`(U,\/>%?&6C^*(]8^P^'IMEG-:^3_:LRY\QX MFW;OLQZ>5C&/XO;GUK%&* ,O$>KZ7??V=X>MOL,,\.S^UIGW^ M:T1SG[,,8\KWSN[8Y@MO"GC.''^@^'F_[BLP_P#;:O6\48JHSE'9F-2A3J.\ ME^9Y1<>&?& %?&6C^*(]8^P>'IMEG-:>3_`&K, MN?,>)MV[[,>GE8QC^+VY]:Q1BG*_\`!W-_\B5U&*,5!N>:>-=%\9>)X=+C_LSP]:_8KS[7G^UY MGW_N98]O_'J,?ZW.>>F._&?;>%/&<./]!\/-_P!Q68?^VU>MXHQ51E*.S,JE M&G4=YH\HG\,^,Y1_R#_#P_[BLW_R-5.P\&>,K3Q%I&J_8_#S_8)WF\K^U)AY MFZ&2+&?LW'^LST/3'?->QXHQ3E4E+=DPP]*#O&/Y_P"9R_VWQE_T`/#W_@[F M_P#D2C[;XR_Z`'A[_P`' ? M[7F??^YECV_\>HQ_K ;R MO[4F'F;H9(L9^S9#')%)K,K(ZD8*L#:8((."#47PG@^S>#1!]EM[3RM1U%/L]L 2C9N\NRN6MYG*_,%2170J20!]Y1S M@G&:YWX3)L\&A?)N(=NHZB/*N9?-E3_3I_E=]S;F'0MN;)R M_MA?\E,TS_L$1?\`HZ:OL/%?'O[8?_)3-,_[!$7_`*.FJ9[%TOB/ISX7#_BV M?A'_`+!%I_Z)2NHQ7,_"T?\`%LO"/_8'L_\`T2E;&HWMQ:W5G%!I=[>I.^V2 M:!H0EN,@;GWR*Q')/R!C\IXZ9I;$O AHTS4++5;&.]TN[MKVSESLGMY5DC?!(.&4D'!!'U%>6RW&F&/Q MS'IDUELL_%FFWEVMNRXA56L6FED`^Z`T4Y=CT*2$GY6KL?`EQ#?WWBO4+&:. MYL+S55DMKF%@\4ZK9VT99''#`.CJ2#U5AU!HN%CJ\5R_PN'_`!;/PC_V"+3_ M`-$I6CK-MX@ENE;1=3TJTMP@#)=Z=)<.6R .*3#[1RN[C)QP?7B@!<48HP=PY&W'(Q M0` *`%Q1BC!W#D;< .*3#[1RN[C)QP?7B@!<48HP M=PY&W'(Q0` *`/*OB[_R./A?_KRO_P#T9:4:/VI?B]_R./A;_KRO_P#T M9:4FC]J^7S/_`'E^B/M,G_W%>K+6K=#63X"_Y*G;?]@>\_\`1UI6MJW0UE>` M?^2IVW_8'O/_`$=:5&7_`.]0^?Y,O,O]PJ?+\T>PXHQ0` .*`#%&*3#[1RN[C)QP?7BEP=PY& MW'(Q0`8HQ0` *7!W#D;< .*`#%&*3#[1RN[C)QP? M7BEP=PY&W'(Q0!E^)IH+;1+F6\UG^PX%V[K_`'Q)Y/S`#F5609.%Y!^]QSBL M+X3/'+X,$D-Y]OB?4M19+O*'SP;Z?$F4`4[NOR@#G@`5O:U!K $?^P/9_P#HE*Z?% S_]$I74 M8IK83W&XHQ7/0^--!ECGD6\D$<:"1&>VE07*E@H:W)4?:`6=`#%OR9(P,[US MJ:-JUGK%JT]B\A".8Y(YH7AEB;`.UXW`=#@JP#`95E(X()8K%W%M$?\`L#V?_HE*ZG%S_P#1*4NH^ATV*,4[%&*8AN*,4[%& M*`&XHQ3L48H`;BC%.Q1B@!N*,4[%&*`&XHQ3L48H`;BC%.Q1B@!N*,4[%&*` M&XHQ3L48H`;BC%.Q1B@!N*,4[%&*`&XHQ3L48H`;BC%.Q1B@!N*,4[%&*`&X MHQ3L48H`\G^+_P#R./A;_KRO_P#T9:4W1^U.^,'_`"./A;_KRO\`_P!&6E-T M?M7S&9_[R_1'V>4?[DO5EK5NAK*\`_\`)4[;_L#WG_HZTK5U;H:R_`'_`"52 MV_[`]Y_Z.M*C+_\`>H_/\F7F7^XU/E^:/8L48IV*,5]4?$C<48IV*,4`-Q1B MG8HQ0`W%&*=BC%`#<48IV*,4`-Q1BG8HQ0`W%&*=BC%`#<48IV*,4`-Q1BG8 MHQ0`W%&*=BC%`#<48IV*,4`-Q1BG8HQ0!E>)K>"YT2YBO-&_MR!MN[3]D3^= M\P(XE94.#AN2/N\ +_P!' M3U]CXKXY_;'_`.2G:9_V!XO_`$=/2GL53W/I_P"%G_),?"'_`&![/_T2E;.H MR:I'=6:Z=9V4]N[XNGGNVA>) /Z[J$OBK6$O8='UZ(:8\3PK+I<\.;>/4+.6>1BZ#<[+`&CBC M#-MC;/SN(T[;P2LDUUXEU+R+F&UU'4EN+;[3"\$C(MI;Q$F-P'7YXG&&`)`R M."">JQ1B@#$UFV\0S72MHNIZ5:6X0!DN].DN'+9.2&6>,`8QQ@]#SS@9_P`+ M@W_"L/"&T@'^R+/J,_\`+%*ZO% ,TN&W#D;< ,U)BC%%P&8; M<.1MQR,4`-DY((SQQTI^*,47`CP^P ..E)A]@Y7=QDXX/KQFI,48HN!Y9\7;/0/%7A+Q%>66K*^M>&[ M&Z=9--ORLUI(!O*2!&P`Q@VE7&>#C!&:Y?XD^$[+P]-=7-M+XIM;>&T1],CL M;R^N$OKUF=?L]P0SE%+?9U7!B+>:P#$CY?;->TBSU[1[K2]3222RND\N9(YG MB+KW7@Z9XZ\('2]0L(KNZAAMK]WU&XF:X-S://LA MCN9"\<>]+4AMN7,J)N!1U;VC5?#=CJDA>YGU5"7,F+;5;JW&2JKTCD48P@XZ M`ECC+,3:.CZ>5TM5M8XX],?S+-(OD2`^4\0VJN!@)(R@8P,].!A*G%.Z2!UI MM -^^M)X[NS@N;2>&>&9%DCFB(9)%(!#*0<$$=#D]>]5)=`TR6QO;22VW17DQ MN)V,C>8TN01)OSN#+M38004"(%VA5Q?M;:"SM8;:TAC@MH4$<442A410,!5` MX``&`!6B,V.PVX ..E)A]@Y7=QDXX/KQFI,48HN`S#;AR-N.1B@ M!LG)!&>..E/Q1BBX$>'V#E=W&3C@^O&:7#;AR-N.1BGXHQ1<##\2'58;8W.G MZMI.F6T"O) QV,KZ7;VUS>#'EQ7,[0QMR,Y=4 OLG%?&_[9/_`"4[3/\`L#Q?^CIZF>Q4-SZA^%G_ M`"3#PA_V![/_`-$)748KF?A6/^+8>$/^P/9_^B$K9U&'5)+JS;3;RRM[9'S= M)<6C3/*N1PC"1`AQNY(?J..,%H3.?E\<6ELS+?:7JUG)*@DL8[B.-7O@98XE MV+O)C)>>!<3",CS!D#:^W9T#6(]8AN?]%N;.ZM)OL]S:W.PR0OL5P"49D.4D M1LJQ&&P<$$#A=8T;6-:U>XU6RT+4=-S]CFN[>_NH7>\:VNX)HD@"32)'M1+D M8)C4O,I.>67K?!UG>1S:]J%_9R6)U2_%U':S.C2Q*MM!#A]C,F2868;6;Y67 M.#D`N%CH<5R_PL_Y)AX0_P"P/9_^B$K1UG1K[4+I9;3Q'JNEQA`IAM([5D8Y M)W'S87;/..#C@<= ";W2M+L].L/&?B**SM(4MX(_*L&V(BA5&3;$G``Y M)S0!V&*,5S/_``C&K?\`0\>(O^_&G_\`R+1_PC&K?]#QXB_[\:?_`/(M%PL= M-BC%P"!GC5B%!MB<9/&2:V?\`A&-6 M_P"AX\1?]^-/_P#D6BX6.FQ1BN9_X1C5O^AX\1?]^-/_`/D6C_A&-6_Z'CQ% M_P!^-/\`_D6BX6.FQ1BN9_X1C5O^AX\1?]^-/_\`D6C_`(1C5O\`H>/$7_?C M3_\`Y%HN%CIL48K@/!6F:YKG@W0=6N_&NO) (O^_&G_\`R+1<+'38HQ7`>"M,US7/!N@ZM=^-=>2YO[""ZE6*WL`@ M9XU8A0;8G&3QDFMG_A&-6_Z'CQ%_WXT__P"1:+A8Z;%&*YG_`(1C5O\`H>/$ M7_?C3_\`Y%H_X1C5O^AX\1?]^-/_`/D6BX6.FQ1BN9_X1C5O^AX\1?\`?C3_ M`/Y%H_X1C5O^AX\1?]^-/_\`D6BX6.FQ1BN`\%:9KFN>#=!U:[\:Z\ES?V$% MU*L5O8!`SQJQ"@VQ.,GC)-;/_",:M_T/'B+_`+\:?_\`(M%PL=-BC% (O^_&G_P#R+1<+'38HQ7,_\(QJW_0\ M>(O^_&G_`/R+1_PC&K?]#QXB_P"_&G__`"+1<+'38HQ7`>"M,US7/!N@ZM=^ M-=>2YO[""ZE6*WL`@9XU8A0;8G&3QDFMG_A&-6_Z'CQ%_P!^-/\`_D6BX6.F MQ1BN9_X1C5O^AX\1?]^-/_\`D6C_`(1C5O\`H>/$7_?C3_\`Y%HN%CIL48KF M?^$8U;_H>/$7_?C3_P#Y%H_X1C5O^AX\1?\`?C3_`/Y%HN%CIL48K@/!6F:Y MKG@W0=6N_&NO) -6(4&V)QD\9)K9_X1C5O^AX M\1?]^-/_`/D6BX6.FQ1BN9_X1C5O^AX\1?\`?C3_`/Y%H_X1C5O^AX\1?]^- M/_\`D6BX6.FQ1BN9_P"$8U;_`*'CQ%_WXT__`.1:/^$8U;_H>/$7_?C3_P#Y M%HN%CIL48K@/!6F:YKG@W0=6N_&NO) (O^_&G_P#R+1<+'38HQ7,_\(QJW_0\>(O^_&G_`/R+1_PC&K?] M#QXB_P"_&G__`"+1<+'38HQ7,_\`",:M_P!#QXB_[\:?_P#(M'_",:M_T/'B M+_OQI_\`\BT7"QTV*,5P'A+3- VH$=O8`;8;J6%3S;'D MK&"??/3I6S_PC&K?]#QXB_[\:?\`_(M%PL=-BC% VH$=O8` M;8;J6%3S;'DK&"??/3I6S_PC&K?]#QXB_P"_&G__`"+1<+&YJJ;]+O$\FYGW M0N/*MI?*E?Y3\J/N7:QZ!MRX.#D=:Y?X1IL\%A/)N8-NI:D/*N9?-E3_`$Z? MY7? OLK%?&O M[9?_`"4_2_\`L#Q?^CYZ4MBH;GU'\*Q_Q:_P?_V![/\`]$)74XKE_A5_R2_P M?_V![/\`]$)74XIH3$Q1BEQ1B@0F*,4N*,4`)BN;N/&N@0-A[R1@KRI*\=K, MZ6_ERO$[S,JD0H'CD&^0JI\MR"0I(Z7%>7>.],DMIO&-G8Z7 )M*N=8.F0W$AN=[Q*YMY%AD MD3.^-)BOENZ[7RBL6&Q\@;&QM8KB+NX.I_$+1Y+%-6F%B\T%S#=Z?+#:0+Y< M@-S%(\:AYBXCC!5V_=R2;5PS-7<8HN`F*,4N*,4"$Q7-W'C70(&P]Y(P5Y4E M>.UF=+?RY7B=YF52(4#QR#?(54^6Y!(4D=+BO+O'>F26TWC&SL=+N3_PD&@K M86(L[1WCDNR]X7$C(I6++7,;%Y"JDNQSPQ!<:/0;[5]/L-2TW3[N[BBOM2=X M[2`G+S%$+O@#L%4DD\#(& *%^(.BZG 7>.],DMIO&-G8Z7 \D8*\J2O' M:S.EOY &(+C1Z#-JUG%K$&EEY'OID,FR*%Y M!&O.&D905C#;6"ERNXJP7)!%7\5Y?X8L=1LO&&`=:.HS:Q?3ZF9TD%I]@83? M9]KE1#(W_'G@@M,J_)D(A1?4<47!B8HQ2XHQ0(3% -=`@;#WDC!7E25X[ M69TM_+E>)WF95(A0/'(-\A53Y;D$A21TN*\N\=Z9);3>,;.QTNY/_"0:"MA8 MBSM'>.2[+WA<2,BE8LM .UF=+ M?RY7B=YF52(4#QR#?(54^6Y!(4D=+BO+O'>F26TWC&SL=+N3_P`)!H*V%B+. MT=XY+LO>%Q(R*5BRUS&Q>0JI+L<\,07&CMK;Q-I5SK!TR&XD-SO>)7-O(L,D MB9WQI,5\MW7:^45BPV/D#8V-K%> 9;:R5E(%Y%, M?W+RRX&Y$^8?:6X5EN&F]'Q1=Y_EA+B&*22V! MD`,:M.JF)6<,A568%O,3`.]<[^*\:\+^%-;BL]$T&W;[+!%_95]KBW=@Y\J> MUAML1V]P'5)-QMHU(57"XE+.#L0^S8H3!H3%&*7%&*!"8K%O/$^C64DD=W?Q M0R1W\.EE7#`M=2JC1Q*,?,2LJ'C(`R21M;&WBN,^)*16>@1RV]A D3.+>1H8Y M'QLC>8+Y:.VY,(S!CO3`.]<[6*\TUBUN_P"V-;TQ;&]:YU'Q%INIVSI;2-"U MO#]B\QFF`\M"/LTWRLP8[1@' >)]&LI)([N_BA MDCOX=+*N&!:ZE5&CB48^8E94/&0!DDC:V-O%<9\24BL]`CEM["YEEGUC3KB8 M6-E)/(_E7,#O(XB5F.(H?O'LJKUVBBXSHVU?3UUZ/13=Q?VK);->"V!RXA5E M0N?0;F`&>O.,[3B_BN2U.4CXJ:`HMKUHQI5]&TZ6DK0HTDMLR*TH78I(@DX) M'0?WESUV*+@)BC%+BC%`A,5BWGB?1K*22.[OXH9([^'2RKA@6NI51HXE&/F) M65#QD`9)(VMC;Q7&?$E(K/0(Y;>PN999]8TZXF%C923R/Y5S`[R.(E9CB*'[ MQ[*J]=HHN,V+GQ-I5MK`TR:XD%SO2)G%O(T, N M=K%<'XSUD7GB"Q\/MIFM/;1WEE<37,&F3R(\BSQO&B2[?+"JRJ\KLV`@*J&9 MB8^]Q1+_`-'SU]F8KXS_`&S/^2H:7_V! MXO\`T?/4RV*CN?4GPJ_Y)?X/_P"P-9_^B$KJ:^)/#_[2'B_0M!TW2;33M`>V ML+:*UB:6"8N4C4*"Q$H&<`9P!5__`(:E\;?]`OPY_P"`\_\`\>HN.Q]F45\9 M_P##4OC;_H%^'/\`P'G_`/CU'_#4OC;_`*!?AS_P'G_^/4[BL?9E%?&?_#4O MC;_H%^'/_`>?_P"/4?\`#4OC;_H%^'/_``'G_P#CU%PL?9E%?&?_``U+XV_Z M!?AS_P`!Y_\`X]1_PU+XV_Z!?AS_`,!Y_P#X]1<+'V917QG_`,-2^-O^@7X< M_P#`>?\`^/4?\-2^-O\`H%^'/_`>?_X]1<+'V917QG_PU+XV_P"@7X<_\!Y_ M_CU'_#4OC;_H%^'/_`>?_P"/47"Q]F45\9_\-2^-O^@7X<_\!Y__`(]1_P`- M2^-O^@7X<_\``>?_`./47"Q]F45\9_\`#4OC;_H%^'/_``'G_P#CU'_#4OC; M_H%^'/\`P'G_`/CU%PL?9E%?&?\`PU+XV_Z!?AS_`,!Y_P#X]1_PU+XV_P"@ M7X<_\!Y__CU%PL?9E%?&?_#4OC;_`*!?AS_P'G_^/4?\-2^-O^@7X<_\!Y__ M`(]1<+'V917QG_PU+XV_Z!?AS_P'G_\`CU'_``U+XV_Z!?AS_P`!Y_\`X]1< M+'V917QG_P`-2^-O^@7X<_\``>?_`./4?\-2^-O^@7X<_P#`>?\`^/47"Q]F M45\9_P##4OC;_H%^'/\`P'G_`/CU'_#4OC;_`*!?AS_P'G_^/47"Q]F45\9_ M\-2^-O\`H%^'/_`>?_X]1_PU+XV_Z!?AS_P'G_\`CU%PL?9E%?&?_#4OC;_H M%^'/_`>?_P"/4?\`#4OC;_H%^'/_``'G_P#CU%PL?9E%?&?_``U+XV_Z!?AS M_P`!Y_\`X]1_PU+XV_Z!?AS_`,!Y_P#X]1<+'V917QG_`,-2^-O^@7X<_P#` M>?\`^/4?\-2^-O\`H%^'/_`>?_X]1<+'V917QG_PU+XV_P"@7X<_\!Y__CU' M_#4OC;_H%^'/_`>?_P"/47"Q]F45\9_\-2^-O^@7X<_\!Y__`(]1_P`-2^-O M^@7X<_\``>?_`./47"Q]F45\9_\`#4OC;_H%^'/_``'G_P#CU'_#4OC;_H%^ M'/\`P'G_`/CU%PL?9E%?&?\`PU+XV_Z!?AS_`,!Y_P#X]1_PU+XV_P"@7X<_ M\!Y__CU%PL?9E%?&?_#4OC;_`*!?AS_P'G_^/4?\-2^-O^@7X<_\!Y__`(]1 M<+'V917QG_PU+XV_Z!?AS_P'G_\`CU'_``U+XV_Z!?AS_P`!Y_\`X]1<+'V9 M17QG_P`-2^-O^@7X<_\``>?_`./4?\-2^-O^@7X<_P#`>?\`^/47"Q]F45\9 M_P##4OC;_H%^'/\`P'G_`/CU'_#4OC;_`*!?AS_P'G_^/47"Q]F45\9_\-2^ M-O\`H%^'/_`>?_X]1_PU+XV_Z!?AS_P'G_\`CU%PL?9E%?&?_#4OC;_H%^'/ M_`>?_P"/4?\`#4OC;_H%^'/_``'G_P#CU%PL?9E%?&?_``U+XV_Z!?AS_P`! MY_\`X]1_PU+XV_Z!?AS_`,!Y_P#X]1<+'V917QG_`,-2^-O^@7X<_P#`>?\` M^/4?\-2^-O\`H%^'/_`>?_X]1<+'V917QG_PU+XV_P"@7X<_\!Y__CU'_#4O MC;_H%^'/_`>?_P"/47"Q]F45\9_\-2^-O^@7X<_\!Y__`(]1_P`-2^-O^@7X M<_\``>?_`./47"Q]F45\9_\`#4OC;_H%^'/_``'G_P#CU'_#4OC;_H%^'/\` MP'G_`/CU%PL?9E%?&?\`PU+XV_Z!?AS_`,!Y_P#X]1_PU+XV_P"@7X<_\!Y_ M_CU%PL?9E?&?[9O_`"5#2_\`L#1?^CYZ/^&I?&W_`$"_#G_@//\`_'J\R^)O FC[5/B+KT&K:W!907,-LMJJVB,J%`SL"0S,
QYKG?AA$T/A:6*2>2X=-4U-6FD" MAY"+Z<%FV@+D]3@`>@%+J.VAU=?'O[87_)3-,_[!$7_HZ:OL/%?'O[8?_)3- M,_[!$7_HZ:IGL72^(^G/A^+9^$?^P1:?\`HE*ZC%MJ]GJC6TEYIEX+1Y[>-HHYLP13!A&S,4P)@N-S9* MYXS@%PL;F*Y?X7#_`(MGX1_[!%I_Z)2M'6?%'A_1+I;;6M=TK3KAT$BQ7=Y' M"Y4D@,`Q!QD$9]C6?\+R%^&/A$L0!_9%F.?^N*4=0MH=/BC%&1N"Y&XC(%`( M)(!!(.#[4Q!BC%)N7:&W+M.,'/!STIE`"XHQ1D;@N1N(R!0""2`02#@^U`!BC%)N7:&W+M.,'/!STI E`"XHQ1D;@N1N(R!0""2`0 M2#@^U`!BC%)N7:&W+M.,'/!STI E`"XHQ1D;@N1N(R!0""2`02#@^U`!BC%)N7:&W+M.,'/!STI E`"XHQ1D;@N1N(R!0""2`02#@^ MU`!BC%)N7:&W+M.,'/!STI E`'E7Q=_Y''PO_`->5_P#^C+2C1^U+\7O^1Q\+?]>5_P#^C+2DT?M7R^9_ M[R_1'VF3_P"XKU9:U;H:R?`7_)4[;_L#WG_HZTK6U;H:RO`/_)4[;_L#WG_H MZTJ,O_WJ'S_)EYE_N%3Y?FCV'%&*`020""0<'VI-R[0VY=IQ@YX.>E?5GQ`N M*,49&X+D;B,@4`@D@$$@X/M0`8HQ2;EVAMR[3C!SP<]*7(W! #GI0`N*,49&X+D;B,@4`@D@$$@X/M0`8HQ2;EV MAMR[3C!SP<]*7(W! #GI0`N*,49 M&X+D;B,@4`@D@$$@X/M0`8HQ2;EVAMR[3C!SP<]*7(W! #GI0`N*,49&X+D;B,@4`@D@$$@X/M0`8HQ2;EVAMR[ M3C!SP<]*7(W! &UFEC@DN'1"RPQ%0\A`R%7<0N3T&2!ZD5S'P MPD>;PM++)!);N^J:FS0RE2\9-_/E6VDKD=#@D>A-;.M>(M$T(Q#6]8TW3C*2 M(_M=TD._&,XW$9QN7/U'K6/\,+B&[\*RW-I-'/;S:KJ MQ5/XCZ>^%O\`R3+PC_V![/\`]$I6SJ.E6^H75G<3R7J/:/OC$%Y-`C'(/SJC M!9!\HX<$=>.3G'^%H_XMCX0_[`]G_P"B4KJ,4UL)[GG-[\*=,^UZ7/I5[J-F MNF0[;6"6]N;F)'66"6+*/+CRU-N`8Q@,"""I16'6>&]'GTM=0FOKJ.ZO]0N? MM5S)#"88MPBCB`1"S%1LB3.6;)W'@$`;6*,46"[&XKF/A;_R3+PC_P!@>S_] M$I74XKE_A:/^+8^$/^P/9_\`HE*.H=#IL48IV*,4Q#<48IV*,4`-Q1BG8HQ0 M`W%&*=BC%`#<48IV*,4`-Q1BG8HQ0`W%&*=BC%`#<48IV*,4`-Q1BG8HQ0`W M%&*=BC%`#<48IV*,4`-Q1BG8HQ0`W%&*=BC%`#<48IV*,4`-Q1BG8HQ0!Y3\ M8H;H>)?#5U#8:C=6\=K>QR-9V \N%DD`>.)(X@"\LDCK'&BY(`+.RJ"2%& H6<%TR37X261Y4WBVM4"$SSX!PA\L,2H!.6V<&(R^G7 MG[23=_Z\CU,-FM;#TO8P2M\_\SE]1UE)@?+TOQ$?^X%>_P#QJD^&\=U/\2([ MHZ;JMO;1Z5=1M+=Z?/;IN::V*J#(B@DA&.!Z&O1_%VLW.AV*W,$&G>0OS3W6 MIZ@+*VA&54!I-CG ,;VV!^RQ7HGDV M&XHQ3L48H`;BC%.Q1B@!N*,4[%&*`&XHQ3L48H`;BC%.Q1B@!N*,4[%&*`&X MHQ3L48H`;BC%.Q1B@!N*,4[%&*`&XHQ3L48H`;BC%.Q1B@!N*YCX=?\`(OW? M_88U3_TON*W]3M9KRQD@M[ZXL)7QBXMUC:1,$'@2*R\XQRIX/8\USGPOB>'P MK+%)/)<.FJZFK32A0\A%_."S;0%R>IP`/0"EU'T.KQ7QU^V-_P`E-TS_`+`\ M7_HZ>OL?%?'/[8__`"4[3/\`L#Q?^CIZ4]BJ>Y]/_"S_`))CX0_[`]G_`.B4 MKJ,5S/PL_P"28^$/^P/9_P#HE*ZC%-$O<;BC%.Q1B@!N*Y?X6?\`),?"'_8' ML_\`T2E=5BN7^%G_`"3'PA_V![/_`-$I0'0Z;%&*=BC%`#<48IV*,4`-Q1BG M8HQ0`W%&*=BC%`#<48IV*,4`-Q1BG8HQ0`W%&*=BC%`#<48IV*,4`-Q1BG8H MQ0`W%&*=BC%`#<48IV*,4`-Q1BG8HQ0`W%&*=BC%`#<48IV*,4`-Q1BG8HQ0 M!S5]X,TF^D>2Z;57D-S]K5AJUVIBDVR+F(B4>6-LKC:F%(.,<#&/'X'UP5 M9>$K?6K8:(NFC3KLS6DDMS*"I61HY#/B/*GY5*N$X'*@*.]Q1B@=V8FJVWB& M60G2=3TJVCWDXN=.DG.W:N!E9TYW!SG'1E&!M);&B\(7L=CI.BKJEM_PC>F_ M8_)@-FWVMOLQC>/=/YFPY>)2<1#*D@8/S#M,48H$Y)JYBC%`#<48IV*,4`-Q1BG8HQ0`W%&*=BC%`#<48IV*,4` M-Q1BG8HQ0`W%&*=BC%`#<48IV*,4`-Q1BG8HQ0`W%&*=BC%`#<48IV*,4`-Q M1BG8HQ0!!=2/#:S2QP27$B(66&(J'D(&0J[B%R>@R0/4BN7^%\CS^%999()+ M=WU74V:&4J7C)OYR5;:2N1T."1Z$UU5U<06=K- VFU74Y(I8F#(ZF_N"&4C@@@@@BCJ/H=7BOCC] ML?\`Y*=IG_8'B_\`1T]?9.*^-_VR?^2G:9_V!XO_`$=/4SV*AN?4/PL_Y)AX M0_[`]G_Z(2NHQ7,_"L?\6P\(?]@>S_\`1"5LZC#JDEU9MIMY96]LCYNDN+1I MGE7(X1A(@0XW ^+;2V:[9+.]N;2W=;?[5"(_*ENFE6);9"S@ MER[JI;'EJVX,ZE6`OZ!K$>L0W/\`HMS9W5I-]GN;6YV&2%]BN`2C,ARDB-E6 M(PV#@@@>5Z1X%U:QTO2;:ST:2TFTFVM5OY'N(V.L36]U:2JT;;R6"I;SK'YW ME[!,B@(I;;Z/X.L[R.;7M0O[.2Q.J7XNH[69T:6)5MH(";W2M+L].L/&?B**SM(4MX(_*L&V(BA5&3;$G``Y M)S0([#%&*YG_`(1C5O\`H>/$7_?C3_\`Y%H_X1C5O^AX\1?]^-/_`/D6BX6. MFQ1BN`\%:9KFN>#=!U:[\:Z\ES?V$%U*L5O8!`SQJQ"@VQ.,GC)-;/\`PC&K M?]#QXB_[\:?_`/(M%PL=-BC% (O^_&G M_P#R+1<+'38HQ7`>"M,US7/!N@ZM=^-=>2YO[""ZE6*WL`@9XU8A0;8G&3QD MFMG_`(1C5O\`H>/$7_?C3_\`Y%HN%CIL48KF?^$8U;_H>/$7_?C3_P#Y%H_X M1C5O^AX\1?\`?C3_`/Y%HN%CIL48KF?^$8U;_H>/$7_?C3__`)%H_P"$8U;_ M`*'CQ%_WXT__`.1:+A8Z;%&*X#P5IFN:YX-T'5KOQKKR7-_8074JQ6]@$#/& MK$*#;$XR>,DUL_\`",:M_P!#QXB_[\:?_P#(M%PL=-BC% (O M^_&G_P#R+1_PC&K?]#QXB_[\:?\`_(M%PL=-BC% -6(4&V)QD\9)K9_X1C5O^AX\1?]^-/_\`D6BX6.FQ1BN9_P"$ M8U;_`*'CQ%_WXT__`.1:/^$8U;_H>/$7_?C3_P#Y%HN%CIL48KF?^$8U;_H> M/$7_`'XT_P#^1:/^$8U;_H>/$7_?C3__`)%HN%CIL48K@/!6F:YKG@W0=6N_ M&NO) (O\`OQI__P`BT7"QTV*,5P'@K3-< MUSP;H.K7?C77DN;^P@NI5BM[`(&>-6(4&V)QD\9)K9_X1C5O^AX\1?\`?C3_ M`/Y%HN%CIL48KF?^$8U;_H>/$7_?C3__`)%H_P"$8U;_`*'CQ%_WXT__`.1: M+A8Z;%&*YG_A&-6_Z'CQ%_WXT_\`^1:/^$8U;_H>/$7_`'XT_P#^1:+A8Z;% M&*X#P5IFN:YX-T'5KOQKKR7-_8074JQ6]@$#/&K$*#;$XR>,DUL_\(QJW_0\ M>(O^_&G_`/R+1<+'38HQ7,_\(QJW_0\>(O\`OQI__P`BT?\`",:M_P!#QXB_ M[\:?_P#(M%PL=-BC% (O^_&G_P#R+1_PC&K?]#QXB_[\:?\` M_(M%PL=-BC%P"!GC5B%!MB<9/&2:V M?^$8U;_H>/$7_?C3_P#Y%HN%CIL48KF?^$8U;_H>/$7_`'XT_P#^1:/^$8U; M_H>/$7_?C3__`)%HN%CIL48KF?\`A&-6_P"AX\1?]^-/_P#D6C_A&-6_Z'CQ M%_WXT_\`^1:+A8Z;%&*X#PEIFN:QI4]S<^-=>62._O;4".WL`-L-U+"IYMCR M5C!/OGITK9_X1C5O^AX\1?\`?C3_`/Y%HN%CIL48KF?^$8U;_H>/$7_?C3__ M`)%H_P"$8U;_`*'CQ%_WXT__`.1:+A8Z;%&*YG_A&-6_Z'CQ%_WXT_\`^1:/ M^$8U;_H>/$7_`'XT_P#^1:+A8Z;%&*X#PEIFN:QI4]S<^-=>62._O;4".WL` M-L-U+"IYMCR5C!/OGITK9_X1C5O^AX\1?]^-/_\`D6BX6.FQ7+_#C_D7KO\` M[#&J_P#IPN*=_P`(QJW_`$/'B+_OQI__`,BUJ>&M%CT'25L8KFYN_P!]-/ M<[/,D>65Y7)V*J_>=N`H&,4`:6*^-_VRO^2GZ7_V!XO_`$?/7V5BOC7]LO\` MY*?I?_8'B_\`1\]*6Q4-SZC^%8_XM?X/_P"P/9_^B$KJ<5R_PJ_Y)?X/_P"P M/9_^B$KJ<4T)B8HQ2XHQ0(3%&*7%&*`$Q7-W'C70(&P]Y(P5Y4E>.UF=+?RY M7B=YF52(4#QR#?(54^6Y!(4D=+BO+O'>F26TWC&SL=+N3_PD&@K86(L[1WCD MNR]X7$C(I6++7,;%Y"JDNQSPQ!<:.VMO$VE7.L'3(;B0W.]XE :"YAN]/EAM(%\N0&YBD M>-0\Q<1Q@J[?NY)-JX9FKN,47`3%&*7%&*!"8KF[CQKH$#8>\D8*\J2O':S. MEOY \+B1D4K%EKF-B\A5278YX8@N-'H-]J^GV&I:;I]W=Q17VI.\=I`3E MYBB%WP!V"J22>!D#.2`;^*\OU'2/%"_$'1=3N=+TZY1]8(-W!>RYBLTMKQ8E M:+R,)A9W8L7;=*^W(5E">HXHN`F*,4N*,4"$Q7-W'C70(&P]Y(P5Y4E>.UF= M+?RY7B=YF52(4#QR#?(54^6Y!(4D=+BO+O'>F26TWC&SL=+N3_PD&@K86(L[ M1WCDNR]X7$C(I6++7,;%Y"JDNQSPQ!<:.\_MVP.N?V1&US+>#AS%:RR11';O MVR2JICC;;@[68'#+Q\RYU,5QJ)%>>.(;K0+"YLYXIG76KN6RDMDNXEB=(TW. MH$["01LKKN"HCC>H<+)V>*+@)BC%+BC%`A,5S=QXUT"!L/>2,%>5)7CM9G2W M\N5XG>9E4B%`\<@WR%5/EN02%)'2XKR[QWIDEM-XQL['2[D_\)!H*V%B+.T= MXY+LO>%Q(R*5BRUS&Q>0JI+L<\,07&CT&;5K.+6(-++R/?3(9-D4+R"-><-( MR@K&&VL%+E=Q5@N2"*OXKR_PQ8ZC9>,,`ZT=1FUB^GU,SI(+3[`PF^S[7*B& M1O\`CSP06F5?DR$0HOJ.*+@Q,48I<48H$)BN;N/&N@0-A[R1@KRI*\=K,Z6_ MERO$[S,JD0H'CD&^0JI\MR"0I(Z7%>7>.],DMIO&-G8Z7 \+B1D4K%EKF-B\A5278YX8@N-'8IXMT=] -Q9S&W>5 M%9GC6?9Y191')D!L@HP/((K?Q7.75M/>_$"PD:&3[#IEA+(6E4^6\\[JL;1G MH71(IPQX*K.H&0[8Z3%%P$Q1BEQ1B@0F*YNX\:Z!`V'O)&"O*DKQVLSI;^7* M\3O,RJ1"@>.0;Y"JGRW()"DCI<5Y=X[TR2VF\8V=CI=R?^$@T%;"Q%G:.\ &(+C1VUMXFTJYU@Z9#<2&YWO$KFWD6&21,[XT MF*^6[KM?**Q8;'R!L;&UBO.=&BN!X^^;2KE%6\NG-JUO,MM9*RD"\BF/[EY9 M<#CXHN`F*,4N*,4"$Q6!J'BW1[&XN+>2:YFNH)C!);VMG- M ($BT7QMIFNM87)LVL[R"YEL;*2X MD:>1K3RRZ1*SG*6[#>1@!%!(RH)<9IKXNT-[Z"UBOO.\_P`L)<0Q226P,@!C M5IU4Q*SAD*JS`MYB8!WKG?Q7C7A?PIK<5GHF@V[?98(O[*OM<6[L'/E3VL-M MB.WN`ZI)N-M&I"JX7$I9P=B'V;%"8-"8HQ2XHQ0(3%8MYXGT:RDDCN[^*&2. M_ATLJX8%KJ54:.)1CYB5E0\9`&22-K8V\5QGQ)2*ST".6WL+F66?6-.N)A8V M4D\C^5 RJO7:*+C-BY\3:5;:P-,FN)!<[TB9Q;R-#'(^-D M;S!?+1VW)A&8,=Z8!WKG:Q7FFL6MW_;&MZ8MC>M M8S3`>6A'V:;Y68,=HP#N7/IF*+A83%&*7%&*!"8K%O/$^C64DD=W?Q0R1W\. MEE7#`M=2JC1Q*,?,2LJ'C(`R21M;&WBN,^)*16>@1RV]A MNT47&;%SXFTJVU@:9-<2"YWI$SBWD:&.1\;(WF"^6CMN3",P8[TP#O7.UBN# M\9ZR+SQ!8^'VTS6GMH[RRN)KF#3)Y$>19XWC1)=OEA595>5V;`0%5#,Q,?>X MHN`F*,4N*,4"$Q7QI^V9_P`E0TO_`+`\7_H^>OLS%?&?[9G_`"5#2_\`L#Q? M^CYZF6Q4=SZD^%7_`"2_P?\`]@:S_P#1"5U-?$GA_P#:0\7Z%H.FZ3::=H#V MUA;16L32P3%RD:A06(E`S@#.`*O_`/#4OC;_`*!?AS_P'G_^/47'8^S**^,_ M^&I?&W_0+\.?^`\__P`>H_X:E\;?]`OPY_X#S_\`QZG<5C[,HKXS_P"&I?&W M_0+\.?\`@//_`/'J/^&I?&W_`$"_#G_@//\`_'J+A8^S**^,_P#AJ7QM_P!` MOPY_X#S_`/QZC_AJ7QM_T"_#G_@//_\`'J+A8^S**^,_^&I?&W_0+\.?^`\_ M_P`>H_X:E\;?]`OPY_X#S_\`QZBX6/LRBOC/_AJ7QM_T"_#G_@//_P#'J/\` MAJ7QM_T"_#G_`(#S_P#QZBX6/LRBOC/_`(:E\;?]`OPY_P"`\_\`\>H_X:E\ M;?\`0+\.?^`\_P#\>HN%C[,HKXS_`.&I?&W_`$"_#G_@//\`_'J/^&I?&W_0 M+\.?^`\__P`>HN%C[,HKXS_X:E\;?]`OPY_X#S__`!ZC_AJ7QM_T"_#G_@// M_P#'J+A8^S**^,_^&I?&W_0+\.?^`\__`,>H_P"&I?&W_0+\.?\`@//_`/'J M+A8^S**^,_\`AJ7QM_T"_#G_`(#S_P#QZC_AJ7QM_P!`OPY_X#S_`/QZBX6/ MLRBOC/\`X:E\;?\`0+\.?^`\_P#\>H_X:E\;?]`OPY_X#S__`!ZBX6/LRBOC M/_AJ7QM_T"_#G_@//_\`'J/^&I?&W_0+\.?^`\__`,>HN%C[,HKXS_X:E\;? M]`OPY_X#S_\`QZC_`(:E\;?]`OPY_P"`\_\`\>HN%C[,HKXS_P"&I?&W_0+\ M.?\`@//_`/'J/^&I?&W_`$"_#G_@//\`_'J+A8^S**^,_P#AJ7QM_P!`OPY_ MX#S_`/QZC_AJ7QM_T"_#G_@//_\`'J+A8^S**^,_^&I?&W_0+\.?^`\__P`> MH_X:E\;?]`OPY_X#S_\`QZBX6/LRBOC/_AJ7QM_T"_#G_@//_P#'J/\`AJ7Q MM_T"_#G_`(#S_P#QZBX6/LRBOC/_`(:E\;?]`OPY_P"`\_\`\>H_X:E\;?\` M0+\.?^`\_P#\>HN%C[,HKXS_`.&I?&W_`$"_#G_@//\`_'J/^&I?&W_0+\.? M^`\__P`>HN%C[,HKXS_X:E\;?]`OPY_X#S__`!ZC_AJ7QM_T"_#G_@//_P#' MJ+A8^S**^,_^&I?&W_0+\.?^`\__`,>H_P"&I?&W_0+\.?\`@//_`/'J+A8^ MS**^,_\`AJ7QM_T"_#G_`(#S_P#QZC_AJ7QM_P!`OPY_X#S_`/QZBX6/LRBO MC/\`X:E\;?\`0+\.?^`\_P#\>H_X:E\;?]`OPY_X#S__`!ZBX6/LRBOC/_AJ M7QM_T"_#G_@//_\`'J/^&I?&W_0+\.?^`\__`,>HN%C[,HKXS_X:E\;?]`OP MY_X#S_\`QZC_`(:E\;?]`OPY_P"`\_\`\>HN%C[,HKXS_P"&I?&W_0+\.?\` M@//_`/'J/^&I?&W_`$"_#G_@//\`_'J+A8^S**^,_P#AJ7QM_P!`OPY_X#S_ M`/QZC_AJ7QM_T"_#G_@//_\`'J+A8^S**^,_^&I?&W_0+\.?^`\__P`>H_X: ME\;?]`OPY_X#S_\`QZBX6/LRBOC/_AJ7QM_T"_#G_@//_P#'J/\`AJ7QM_T" M_#G_`(#S_P#QZBX6/LRBOC/_`(:E\;?]`OPY_P"`\_\`\>H_X:E\;?\`0+\. M?^`\_P#\>HN%C[,HKXS_`.&I?&W_`$"_#G_@//\`_'J/^&I?&W_0+\.?^`\_ M_P`>HN%C[,HKXS_X:E\;?]`OPY_X#S__`!ZC_AJ7QM_T"_#G_@//_P#'J+A8 M^S*^,_VS?^2H:7_V!HO_`$?/1_PU+XV_Z!?AS_P'G_\`CU>9?$WQ]JGQ%UZ# ?5M;@LH+F&V6U5;1&5"@9V!(9F. _I4R>A45J?_V0`` ` end
Label | Element | Value | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Risk/Return: | rr_RiskReturnAbstract | |||||||||||
Registrant Name | dei_EntityRegistrantName | BLACKROCK FUNDS | ||||||||||
Prospectus Date | rr_ProspectusDate | Jan. 28, 2013 | ||||||||||
Investor, Institutional and R Shares | BLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO
|
||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||
Risk/Return [Heading] | rr_RiskReturnHeading | Fund Overview Key Facts About BlackRock Health Sciences Opportunities Portfolio |
||||||||||
Objective [Heading] | rr_ObjectiveHeading | Investment Objective | ||||||||||
Objective, Primary [Text Block] | rr_ObjectivePrimaryTextBlock | The investment objective of BlackRock Health Sciences Opportunities Portfolio (“Health Sciences Opportunities” or the “Fund”), a series of BlackRock FundsSM (the “Trust”), is to provide long-term growth of capital. | ||||||||||
Expense [Heading] | rr_ExpenseHeading | Fees and Expenses of the Fund | ||||||||||
Expense Narrative [Text Block] | rr_ExpenseNarrativeTextBlock | This table describes the fees and expenses that you may pay if you buy and hold shares of Health Sciences Opportunities. You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $25,000 in the fund complex advised by BlackRock Advisors, LLC (“BlackRock”). More information about these and other discounts is available from your financial professional and in the “Details About the Share Classes” section on page 47 of the Fund’s prospectus and in the “Purchase of Shares” section on page II-58 of the Fund’s statement of additional information. | ||||||||||
Shareholder Fees Caption [Text] | rr_ShareholderFeesCaption | Shareholder Fees (fees paid directly from your investment) |
||||||||||
Operating Expenses Caption [Text] | rr_OperatingExpensesCaption | Annual Fund Operating Expenses (expenses that you pay each year as a percentage of the value of your investment) |
||||||||||
Fee Waiver or Reimbursement over Assets, Date of Termination | rr_FeeWaiverOrReimbursementOverAssetsDateOfTermination | February 1, 2014 | ||||||||||
Portfolio Turnover [Heading] | rr_PortfolioTurnoverHeading | Portfolio Turnover: | ||||||||||
Portfolio Turnover [Text Block] | rr_PortfolioTurnoverTextBlock | The Fund pays transaction costs, such as commissions, when it buys and sells securities (or “turns over” its portfolio). A higher portfolio turnover may indicate higher transaction costs and may result in higher taxes when shares are held in a taxable account. These costs, which are not reflected in annual fund operating expenses or in the example, affect the Fund’s performance. During the most recent fiscal year, the Fund’s portfolio turnover rate was 135% of the average value of its portfolio. | ||||||||||
Portfolio Turnover, Rate | rr_PortfolioTurnoverRate | 135.00% | ||||||||||
Expenses Deferred Charges [Text Block] | rr_ExpensesDeferredChargesTextBlock | A contingent deferred sales charge (“CDSC”) of 1.00% is assessed on certain redemptions of Investor A Shares made within 18 months after purchase where no initial sales charge was paid at time of purchase as part of an investment of $1,000,000 or more. | ||||||||||
Expense Breakpoint Discounts [Text] | rr_ExpenseBreakpointDiscounts | You may qualify for sales charge discounts if you and your family invest, or agree to invest in the future, at least $25,000 in the fund complex advised by BlackRock Advisors, LLC (“BlackRock”). | ||||||||||
Expense Breakpoint, Minimum Investment Required [Amount] | rr_ExpenseBreakpointMinimumInvestmentRequiredAmount | 25,000 | ||||||||||
Expenses Not Correlated to Ratio Due to Acquired Fund Fees [Text] | rr_ExpensesNotCorrelatedToRatioDueToAcquiredFundFees | The Total Annual Fund Operating Expenses do not correlate to the ratio of expenses to average net assets given in the Fund’s most recent annual report which does not include the Acquired Fund Fees and Expenses. | ||||||||||
Expense Example [Heading] | rr_ExpenseExampleHeading | Example: | ||||||||||
Expense Example Narrative [Text Block] | rr_ExpenseExampleNarrativeTextBlock | This Example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The Example assumes that you invest $10,000 in the Fund for the time periods indicated and then redeem all of your shares at the end of those periods. The Example also assumes that your investment has a 5% return each year and that the Fund’s operating expenses remain the same. Although your actual costs may be higher or lower, based on these assumptions your costs would be: | ||||||||||
Expense Example, No Redemption, By Year, Caption [Text] | rr_ExpenseExampleNoRedemptionByYearCaption | You would pay the following expenses if you did not redeem your shares: | ||||||||||
Strategy [Heading] | rr_StrategyHeading | Principal Investment Strategies of the Fund | ||||||||||
Strategy Narrative [Text Block] | rr_StrategyNarrativeTextBlock | Under normal market conditions, Health Sciences Opportunities invests at least 80% of total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The health sciences sector can include companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. Health sciences and related industries can include, but are not limited to, businesses involved in the development, production, and distribution or delivery of medical and pharmaceutical products and services, companies engaged in biotechnology and medical research and development, companies that may design, manufacture or distribute medical, dental and optical equipment and supplies, including diagnostic equipment, and companies that may also provide diagnostic services or operate health facilities and hospitals, or provide related administrative, management and financial support. The Fund will concentrate its investments (i.e., invest more than 25% of its assets) in health sciences or related industries, and may invest in companies located in non-U.S. countries. The Fund reserves the right to invest up to 20% of total assets in other types of securities. These may include stocks of companies not associated with health sciences. The Fund is classified as non-diversified under the Investment Company Act of 1940, as amended, which means that it can invest more of its assets in fewer companies than a diversified fund. |
||||||||||
Strategy Portfolio Concentration [Text] | rr_StrategyPortfolioConcentration | The Fund will concentrate its investments (i.e., invest more than 25% of its assets) in health sciences or related industries, and may invest in companies located in non-U.S. countries. | ||||||||||
Risk [Heading] | rr_RiskHeading | Principal Risks of Investing in the Fund | ||||||||||
Risk Narrative [Text Block] | rr_RiskNarrativeTextBlock | Risk is inherent in all investing. The value of your investment in Health Sciences Opportunities, as well as the amount of return you receive on your investment, may fluctuate significantly from day to day and over time. You may lose part or all of your investment in the Fund or your investment may not perform as well as other similar investments. The following is a summary description of principal risks of investing in the Fund.
|
||||||||||
Risk Lose Money [Text] | rr_RiskLoseMoney | You may lose part or all of your investment in the Fund or your investment may not perform as well as other similar investments. | ||||||||||
Risk Nondiversified Status [Text] | rr_RiskNondiversifiedStatus | Non-Diversification Risk — The Fund is a non-diversified fund. Because the Fund may invest in securities of a smaller number of issuers, it may be more exposed to the risks associated with and developments affecting an individual issuer than a fund that invests more widely. | ||||||||||
Bar Chart and Performance Table [Heading] | rr_BarChartAndPerformanceTableHeading | Performance Information | ||||||||||
Performance Narrative [Text Block] | rr_PerformanceNarrativeTextBlock | On January 31, 2005, Health Sciences Opportunities reorganized with the State Street Research Health Sciences Fund (the “SSR Fund”). For periods prior to January 31, 2005, the chart and table show performance information for the SSR Fund, which had investment objectives and strategies substantially similar to the Fund. The performance of Investor B and Investor C Shares for the period before they were launched is based on the performance of Investor A Shares, adjusted to reflect the class specific fees applicable to Investor B and Investor C Shares, respectively, at the time of such share class’ launch. Class R Shares commenced operations on September 12, 2011, therefore the returns in the table for Class R Shares prior to commencement date are based on the Fund’s Institutional Shares, adjusted to reflect the fees and expenses applicable to Class R Shares. This information may be considered when assessing the Fund’s performance, but does not represent the actual performance of these share classes. The information shows you how the Fund’s performance has varied year by year and provides some indication of the risks of investing in the Fund. The table compares the Fund’s performance to that of the Standard & Poor’s (“S&P”) 500® Index. The table also compares the Fund’s performance to that of the Russell 3000® Health Care Index, which is relevant to the Fund because it has characteristics similar to the Fund’s investment strategies. As with all such investments, past performance (before and after taxes) is not an indication of future results. Sales charges are not reflected in the bar chart. If they were, returns would be less than those shown. However, the table includes all applicable fees and sales charges. If BlackRock and its affiliates had not waived or reimbursed certain Fund expenses during these periods, the Fund’s returns would have been lower. Updated information on the Fund’s results can be obtained by visiting http://www.blackrock.com/funds or can be obtained by phone at (800) 882-0052. |
||||||||||
Performance Information Illustrates Variability of Returns [Text] | rr_PerformanceInformationIllustratesVariabilityOfReturns | The information shows you how the Fund’s performance has varied year by year and provides some indication of the risks of investing in the Fund. | ||||||||||
Performance Availability Phone [Text] | rr_PerformanceAvailabilityPhone | (800) 882-0052 | ||||||||||
Performance Availability Website Address [Text] | rr_PerformanceAvailabilityWebSiteAddress | http://www.blackrock.com/funds | ||||||||||
Performance Past Does Not Indicate Future [Text] | rr_PerformancePastDoesNotIndicateFuture | As with all such investments, past performance (before and after taxes) is not an indication of future results. | ||||||||||
Bar Chart [Heading] | rr_BarChartHeading | Investor A Shares ANNUAL TOTAL RETURNS BlackRock Health Sciences Opportunities Portfolio As of 12/31 |
||||||||||
Bar Chart Does Not Reflect Sales Loads [Text] | rr_BarChartDoesNotReflectSalesLoads | Sales charges are not reflected in the bar chart. If they were, returns would be less than those shown. | ||||||||||
Bar Chart Closing [Text Block] | rr_BarChartClosingTextBlock | During the ten-year period shown in the bar chart, the highest return for a quarter was 34.69% (quarter ended June 30, 2003) and the lowest return for a quarter was –13.97% (quarter ended December 31, 2008). | ||||||||||
Performance Table Heading | rr_PerformanceTableHeading | As of 12/31/12 Average Annual Total Returns |
||||||||||
Performance Table Does Reflect Sales Loads | rr_PerformanceTableDoesReflectSalesLoads | However, the table includes all applicable fees and sales charges. | ||||||||||
Performance Table Uses Highest Federal Rate | rr_PerformanceTableUsesHighestFederalRate | After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. | ||||||||||
Performance Table Not Relevant to Tax Deferred | rr_PerformanceTableNotRelevantToTaxDeferred | Actual after-tax returns depend on the investor’s tax situation and may differ from those shown, and the after-tax returns shown are not relevant to investors who hold their shares through tax-deferred arrangements such as 401(k) plans or individual retirement accounts. | ||||||||||
Performance Table One Class of after Tax Shown [Text] | rr_PerformanceTableOneClassOfAfterTaxShown | After-tax returns are shown for Investor A Shares only, and the after-tax returns for Investor B, Investor C, Institutional and Class R Shares will vary. | ||||||||||
Performance Table Narrative | rr_PerformanceTableNarrativeTextBlock | After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on the investor’s tax situation and may differ from those shown, and the after-tax returns shown are not relevant to investors who hold their shares through tax-deferred arrangements such as 401(k) plans or individual retirement accounts. After-tax returns are shown for Investor A Shares only, and the after-tax returns for Investor B, Investor C, Institutional and Class R Shares will vary. | ||||||||||
Investor, Institutional and R Shares | BLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO | Investor A Shares
|
||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||
Maximum Sales Charge (Load) Imposed on Purchases (as percentage of offering price) | rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice | 5.25% | ||||||||||
Maximum Deferred Sales Charge (Load) (as percentage of offering price or redemption proceeds, whichever is lower) | rr_MaximumDeferredSalesChargeOverOfferingPrice | none | [1] | |||||||||
Management Fees | rr_ManagementFeesOverAssets | 0.73% | ||||||||||
Distribution (12b-1) and/or Service Fees | rr_DistributionAndService12b1FeesOverAssets | 0.25% | ||||||||||
Other Expenses | rr_OtherExpensesOverAssets | 0.31% | ||||||||||
Acquired Fund Fees and Expenses | rr_AcquiredFundFeesAndExpensesOverAssets | 0.01% | [2] | |||||||||
Total Annual Fund Operating Expenses | rr_ExpensesOverAssets | 1.30% | [2] | |||||||||
Fee Waivers and/or Expense Reimbursements | rr_FeeWaiverOrReimbursementOverAssets | [3] | ||||||||||
Total Annual Fund Operating Expenses After Fee Waivers and/or Expense Reimbursements | rr_NetExpensesOverAssets | 1.30% | [3] | |||||||||
1 Year | rr_ExpenseExampleYear01 | 650 | ||||||||||
3 Years | rr_ExpenseExampleYear03 | 915 | ||||||||||
5 Years | rr_ExpenseExampleYear05 | 1,200 | ||||||||||
10 Years | rr_ExpenseExampleYear10 | 2,010 | ||||||||||
2003 | rr_AnnualReturn2003 | 66.64% | ||||||||||
2004 | rr_AnnualReturn2004 | 14.56% | ||||||||||
2005 | rr_AnnualReturn2005 | 16.83% | ||||||||||
2006 | rr_AnnualReturn2006 | 8.24% | ||||||||||
2007 | rr_AnnualReturn2007 | 20.35% | ||||||||||
2008 | rr_AnnualReturn2008 | (19.33%) | ||||||||||
2009 | rr_AnnualReturn2009 | 27.25% | ||||||||||
2010 | rr_AnnualReturn2010 | 7.16% | ||||||||||
2011 | rr_AnnualReturn2011 | 5.97% | ||||||||||
2012 | rr_AnnualReturn2012 | 18.39% | ||||||||||
Highest Quarterly Return, Label | rr_HighestQuarterlyReturnLabel | highest return | ||||||||||
Highest Quarterly Return, Date | rr_BarChartHighestQuarterlyReturnDate | Jun. 30, 2003 | ||||||||||
Highest Quarterly Return | rr_BarChartHighestQuarterlyReturn | 34.69% | ||||||||||
Lowest Quarterly Return, Label | rr_LowestQuarterlyReturnLabel | lowest return | ||||||||||
Lowest Quarterly Return, Date | rr_BarChartLowestQuarterlyReturnDate | Dec. 31, 2008 | ||||||||||
Lowest Quarterly Return | rr_BarChartLowestQuarterlyReturn | (13.97%) | ||||||||||
1 Year | rr_AverageAnnualReturnYear01 | 12.17% | ||||||||||
5 Years | rr_AverageAnnualReturnYear05 | 5.51% | ||||||||||
10 Years | rr_AverageAnnualReturnYear10 | 14.28% | ||||||||||
Investor, Institutional and R Shares | BLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO | Investor B Shares
|
||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||
Maximum Sales Charge (Load) Imposed on Purchases (as percentage of offering price) | rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice | none | ||||||||||
Maximum Deferred Sales Charge (Load) (as percentage of offering price or redemption proceeds, whichever is lower) | rr_MaximumDeferredSalesChargeOverOfferingPrice | 4.50% | [4] | |||||||||
Management Fees | rr_ManagementFeesOverAssets | 0.73% | ||||||||||
Distribution (12b-1) and/or Service Fees | rr_DistributionAndService12b1FeesOverAssets | 1.00% | ||||||||||
Other Expenses | rr_OtherExpensesOverAssets | 0.34% | ||||||||||
Acquired Fund Fees and Expenses | rr_AcquiredFundFeesAndExpensesOverAssets | 0.01% | [2] | |||||||||
Total Annual Fund Operating Expenses | rr_ExpensesOverAssets | 2.08% | [2] | |||||||||
Fee Waivers and/or Expense Reimbursements | rr_FeeWaiverOrReimbursementOverAssets | [3] | ||||||||||
Total Annual Fund Operating Expenses After Fee Waivers and/or Expense Reimbursements | rr_NetExpensesOverAssets | 2.08% | [3] | |||||||||
1 Year | rr_ExpenseExampleYear01 | 661 | ||||||||||
3 Years | rr_ExpenseExampleYear03 | 1,002 | ||||||||||
5 Years | rr_ExpenseExampleYear05 | 1,319 | ||||||||||
10 Years | rr_ExpenseExampleYear10 | 2,211 | ||||||||||
1 Year | rr_ExpenseExampleNoRedemptionYear01 | 211 | ||||||||||
3 Years | rr_ExpenseExampleNoRedemptionYear03 | 652 | ||||||||||
5 Years | rr_ExpenseExampleNoRedemptionYear05 | 1,119 | ||||||||||
10 Years | rr_ExpenseExampleNoRedemptionYear10 | 2,211 | ||||||||||
1 Year | rr_AverageAnnualReturnYear01 | 12.99% | ||||||||||
5 Years | rr_AverageAnnualReturnYear05 | 5.50% | ||||||||||
10 Years | rr_AverageAnnualReturnYear10 | 14.19% | ||||||||||
Investor, Institutional and R Shares | BLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO | Investor C Shares
|
||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||
Maximum Sales Charge (Load) Imposed on Purchases (as percentage of offering price) | rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice | none | ||||||||||
Maximum Deferred Sales Charge (Load) (as percentage of offering price or redemption proceeds, whichever is lower) | rr_MaximumDeferredSalesChargeOverOfferingPrice | 1.00% | [5] | |||||||||
Management Fees | rr_ManagementFeesOverAssets | 0.73% | ||||||||||
Distribution (12b-1) and/or Service Fees | rr_DistributionAndService12b1FeesOverAssets | 1.00% | ||||||||||
Other Expenses | rr_OtherExpensesOverAssets | 0.28% | ||||||||||
Acquired Fund Fees and Expenses | rr_AcquiredFundFeesAndExpensesOverAssets | 0.01% | [2] | |||||||||
Total Annual Fund Operating Expenses | rr_ExpensesOverAssets | 2.02% | [2] | |||||||||
Fee Waivers and/or Expense Reimbursements | rr_FeeWaiverOrReimbursementOverAssets | [3] | ||||||||||
Total Annual Fund Operating Expenses After Fee Waivers and/or Expense Reimbursements | rr_NetExpensesOverAssets | 2.02% | [3] | |||||||||
1 Year | rr_ExpenseExampleYear01 | 305 | ||||||||||
3 Years | rr_ExpenseExampleYear03 | 634 | ||||||||||
5 Years | rr_ExpenseExampleYear05 | 1,088 | ||||||||||
10 Years | rr_ExpenseExampleYear10 | 2,348 | ||||||||||
1 Year | rr_ExpenseExampleNoRedemptionYear01 | 205 | ||||||||||
3 Years | rr_ExpenseExampleNoRedemptionYear03 | 634 | ||||||||||
5 Years | rr_ExpenseExampleNoRedemptionYear05 | 1,088 | ||||||||||
10 Years | rr_ExpenseExampleNoRedemptionYear10 | 2,348 | ||||||||||
1 Year | rr_AverageAnnualReturnYear01 | 16.58% | ||||||||||
5 Years | rr_AverageAnnualReturnYear05 | 5.89% | ||||||||||
10 Years | rr_AverageAnnualReturnYear10 | 14.08% | ||||||||||
Investor, Institutional and R Shares | BLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO | Institutional Shares
|
||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||
Maximum Sales Charge (Load) Imposed on Purchases (as percentage of offering price) | rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice | none | ||||||||||
Maximum Deferred Sales Charge (Load) (as percentage of offering price or redemption proceeds, whichever is lower) | rr_MaximumDeferredSalesChargeOverOfferingPrice | none | ||||||||||
Management Fees | rr_ManagementFeesOverAssets | 0.73% | ||||||||||
Distribution (12b-1) and/or Service Fees | rr_DistributionAndService12b1FeesOverAssets | none | ||||||||||
Other Expenses | rr_OtherExpensesOverAssets | 0.25% | ||||||||||
Acquired Fund Fees and Expenses | rr_AcquiredFundFeesAndExpensesOverAssets | 0.01% | [2] | |||||||||
Total Annual Fund Operating Expenses | rr_ExpensesOverAssets | 0.99% | [2] | |||||||||
Fee Waivers and/or Expense Reimbursements | rr_FeeWaiverOrReimbursementOverAssets | [3] | ||||||||||
Total Annual Fund Operating Expenses After Fee Waivers and/or Expense Reimbursements | rr_NetExpensesOverAssets | 0.99% | [3] | |||||||||
1 Year | rr_ExpenseExampleYear01 | 101 | ||||||||||
3 Years | rr_ExpenseExampleYear03 | 315 | ||||||||||
5 Years | rr_ExpenseExampleYear05 | 547 | ||||||||||
10 Years | rr_ExpenseExampleYear10 | 1,213 | ||||||||||
1 Year | rr_AverageAnnualReturnYear01 | 18.77% | ||||||||||
5 Years | rr_AverageAnnualReturnYear05 | 6.99% | ||||||||||
10 Years | rr_AverageAnnualReturnYear10 | 15.25% | ||||||||||
Investor, Institutional and R Shares | BLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO | Class R Shares
|
||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||
Maximum Sales Charge (Load) Imposed on Purchases (as percentage of offering price) | rr_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice | none | ||||||||||
Maximum Deferred Sales Charge (Load) (as percentage of offering price or redemption proceeds, whichever is lower) | rr_MaximumDeferredSalesChargeOverOfferingPrice | none | ||||||||||
Management Fees | rr_ManagementFeesOverAssets | 0.73% | ||||||||||
Distribution (12b-1) and/or Service Fees | rr_DistributionAndService12b1FeesOverAssets | 0.50% | ||||||||||
Other Expenses | rr_OtherExpensesOverAssets | 0.47% | ||||||||||
Acquired Fund Fees and Expenses | rr_AcquiredFundFeesAndExpensesOverAssets | 0.01% | [2] | |||||||||
Total Annual Fund Operating Expenses | rr_ExpensesOverAssets | 1.71% | [2] | |||||||||
Fee Waivers and/or Expense Reimbursements | rr_FeeWaiverOrReimbursementOverAssets | [3] | ||||||||||
Total Annual Fund Operating Expenses After Fee Waivers and/or Expense Reimbursements | rr_NetExpensesOverAssets | 1.71% | [3] | |||||||||
1 Year | rr_ExpenseExampleYear01 | 174 | ||||||||||
3 Years | rr_ExpenseExampleYear03 | 539 | ||||||||||
5 Years | rr_ExpenseExampleYear05 | 928 | ||||||||||
10 Years | rr_ExpenseExampleYear10 | 2,019 | ||||||||||
1 Year | rr_AverageAnnualReturnYear01 | 17.92% | ||||||||||
5 Years | rr_AverageAnnualReturnYear05 | 6.17% | ||||||||||
10 Years | rr_AverageAnnualReturnYear10 | 14.35% | ||||||||||
Investor, Institutional and R Shares | BLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO | Return After Taxes On Distributions | Investor A Shares
|
||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||
1 Year | rr_AverageAnnualReturnYear01 | 10.80% | ||||||||||
5 Years | rr_AverageAnnualReturnYear05 | 4.51% | ||||||||||
10 Years | rr_AverageAnnualReturnYear10 | 13.32% | ||||||||||
Investor, Institutional and R Shares | BLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO | Return After Taxes On Distributions And Sale Of Shares | Investor A Shares
|
||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||
1 Year | rr_AverageAnnualReturnYear01 | 9.25% | ||||||||||
5 Years | rr_AverageAnnualReturnYear05 | 4.42% | ||||||||||
10 Years | rr_AverageAnnualReturnYear10 | 12.48% | ||||||||||
Investor, Institutional and R Shares | BLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO | Russell 3000® Health Care Index (Reflects no deduction for fees, expenses or taxes)
|
||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||
1 Year | rr_AverageAnnualReturnYear01 | 19.32% | ||||||||||
5 Years | rr_AverageAnnualReturnYear05 | 5.52% | ||||||||||
10 Years | rr_AverageAnnualReturnYear10 | 7.13% | ||||||||||
Investor, Institutional and R Shares | BLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO | S&P 500® Index (Reflects no deduction for fees, expenses or taxes)
|
||||||||||||
Risk/Return: | rr_RiskReturnAbstract | |||||||||||
1 Year | rr_AverageAnnualReturnYear01 | 16.00% | ||||||||||
5 Years | rr_AverageAnnualReturnYear05 | 1.66% | ||||||||||
10 Years | rr_AverageAnnualReturnYear10 | 7.10% | ||||||||||
|
`-S%F8I+,R78D9)"HHJ@C38C$K>PKL$D$U!#D:Z/-8PM/:G M%W=\=N7,M@@:&1"C'Q]^#_JID?"3V&[H5Z"0/KL93/<"ZF_)@X;YI/B+]D$D M9ZX,?&6WDT\B7MJ1AT'7,).LE>QO?Y09^4KHS[LF(\7,Y%R!P+6_=:C&MR!5 M*M>UH;1!Q)@?^&>L&G)VV;EYKC+1#8.XGVZDG`?K5'E_@,[01&U(8LPI,S8. M6=J]1GDQW`?2<)7IJVM34JZI6+EIHHPJ'`5>LC6C4@2H0SEYE(<3>+$'%CC' M*\@[%HM0*@>YB-O_R.^FZ._9_)[P\^E[@5MGTT9AB$U7"X&)&+C$![U02*!+ MH-5U3QZ]8.IG6F\P
B#F,&8
MK)W Q3?21Q02`>-%>@Z<`*,8#Y0R;PC19H]1
M)-P$OCRB)1^P"%$/6A!-*L=F+IFR5L,/2U%E)@YI[C29>Q/\VY4Y`Z%L!!H,
M/?>!U%3,4**UBQA`SOFX4;(3A10,A\FM@)RE:Q1IO2R)UZ)B`A`#UG3/5U0)
MR>^1W`S&N5319D$4D;A"1P^?E>?^:^YBK`69!^IK\I`F%+0Q$,V"7_H]6%F3
M?B`37L0_9GM1H`(Q^^1BGA0IIDYJ0=B+*Q-/T)D@OLWP&7,=^%$DW\S/D(!(
M43=>YK$[`?K!?"[5D58MP!S(&8W0C@"IDB8=Q"@&L8GE4)#;(HT7H/&$C'>K
M\$/.[H!9.[&4W%(PR;O#%!(ATF\Y`NZ)!S?R9)(H*G.T55\\22W25&W2M] O ],:!.F7>B7>3H&U
MCO^4TZP-G70J,.1-,4)R,!I399] ^!8
M'B;%A#K3PR!.VAUIND:8F;&K!Y(GD).,)ZU$OPCV$=,%B1IY>%[:%AZ1YSSD
M/:MT(0V]#%D3QH0^)E)OGQX#3Q#YOD[H]/7<4W]N3M3:=+M+%+\UU"TWHGF:
MDV<"+A1X[$-AG-+#H7@@LAN+8:R?_D62-.JZ$_4&,J(I'$<)/$!0HI%.[RIX
M]3R:DVTP@?^%([J&`QZS?ZY18*Z2U0E&PS\IFA#HH>!)-)[\;2&?()(%7#1R
M?F'G)+(DY5Y1'\5<%.&/98QD/!*>RH--DX&-0ZHT_E-L<
M/G'(U^4IW
U"_"^2[J/,H=NHC\R[IVS,+=5E@K-H9`K9!*XA=ZMZK$71NO:.4=[1`L9U%Y:02JO:`'$OT(GX%02M;V<7!+)5TVV0X0@#05,!P$JA#62
M^8R61W99A#4;=ZK(%HP+!7&2$AS:Q`CY^;F;&)FR:K17ER@1HX[10DYIRX
M-XD/,/C9-2$]<4F?0F.AN9RAI'41>)NY2)).2N\DQY)R\C+-2&V1QSD275`0
MG;H
'*C[<75U;ETBJ9.@L
MK+\'(=PKZKQAO?W&O.$TV/XTV+[.P?8Z%:_BA%3YM6RX8(XCN/SX\?/E>^O^
MYA[^]_;M_>?;CW?F]UOV#TDMG4Q#*$A\S6:YJL^O0*V#SROCA4;E92S\,V);
M3(^RZ7WV'C*5IM->2
0D%.7ILG!AT\H=]P8?8%2E1>>%^'DMGG(=08O@5<;&?RL
M9B$D9@&!"X#^'^PC.``[K99MGO]:>;
M*#6%>LU9P.NE[H^W'V@3B5<[Q);X2E[AA4&0P0K(O&KE\51\QP2@.7&0$,.(![^DR*2%(J!#$#NC9<)
M5'R#-4'C,;;X,H"+_N#P14#9;UPSXU+@1&P+B88,PM2X^U?G*?5[A8-TRW3A
M[IX9@=4HZ?ND"^>#N7?!1@5@MIIK6W+@/)[#F8.W:FSI=6YX)6=6T)9IT-V]
MTQHK/(;520T(;?7&(+Z%`V'`R.0H7[2L=""+V5%1/@(^OKF]V#`G_Y+/:8IF
M#:XK(TD8!4//%G4U\;-O:Q!'G'ASC`H!QT)A!LK3R/%C8.QDM(T=,G;P/\BZ
MR=V%:M.Y5?<\8\(C6%9>\$1TSE)^BMU'9/HEYZR@]-$79,U<7[P@
;
7]]\_'R_
`NUQEAU^^,L(N=$4>#NUSKT*[?.K2+K<-CP5TK-R&H57\^4*LX'>AH<)>K
MW[7JU^]:QZ_?M7/MZW;]]G6[V+X^&MSEZL;M^G7C]O'KQNU<':5=OX[2/GX=
MI9VKH[3KUU':QZ^C='+O;*?^.]LY_CO;R;5G._7;LYWCMV<[N?9LIWY[MG/\
M]FPG5U9TZI<5G>.7%=W